Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics Authors: Ruiyi Deng, Boyuan Wang, Mingrui Zou, Kaiyuan Mao, Jiaheng Shang, Jianhui Qiu, Jingcheng Zhou, Hua Xu, Xin Ma, Yizhou Wang, Lin Cai, Kan Gong Published: 2026 ABSTRACT The von Hippel-Lindau (VHL) gene encodes the core substrate-recognition subunit of the Cullin2-RING E3 ubiquitin ligase complex, regulating cellular oxygen sensing and proteostasis. While targeting the canonical VHL-hypoxia-inducible factor (HIF) axis (e.g. belzutifan) has improved advanced clear cell renal cell carcinoma (ccRCC) management, intrinsic non-responsiveness and acquired resistance to HIF-2α inhibitors present major clinical limitations. Expanding beyond the HIF-centric paradigm reveals a broader network of non-canonical VHL targets, offering new opportunities for therapeutic development across ccRCC and pan-cancer contexts. This review provides an evidence-graded synthesis of novel VHL targets spanning epigenetic regulation (e.g. ZHX2, SETDB1, METTL3/METTL14), metabolic reprogramming (e.g. NDRG3, TFAM), extracellular matrix architecture (e.g. fibronectin, COL4A2), and immune modulation (e.g. TBK1). Supporting evidence across these targets ranges from direct biochemical ubiquitination to indirect downstream observations, derived predominantly from preclinical cell-line and xenograft models. Disruption of VHL and these non-HIF networks contributes to oncogenesis across diverse malignancies. Translating these mechanistic insights catalyzes two distinct therapeutic modalities. For VHL-deficient malignancies, selectively intercepting unshielded downstream effectors with small-molecule inhibitors provides rational, vulnerability-targeted salvage strategies. Conversely, in VHL-proficient malignancies, the exceptional chemical tractability of VHL has been repurposed by proteolysis targeting chimeras (PROTACs). VHL-recruiting PROTACs hijack operational ligase machinery to degrade targeted oncogenic drivers, including some previously “undruggable” oncogenes. These next-generation degraders offer potential biomarker-driven strategies to overcome current therapeutic bottlenecks in ccRCC and other associated malignancies. However, current evidence derives predominantly from in vitro and animal models. Realizing the clinical potential of VHL-targeted strategies requires addressing key unresolved questions regarding substrate directness, tissue tropism, and resistance trade-offs. Further investigating these core mechanistic and pharmacological bottlenecks will be essential to guide next-generation therapies in VHL-associated malignancies. Background VHL and the clinical dilemma in ccRCC The von Hippel-Lindau (VHL) gene, located on chromosome 3p25, encodes a key tumor suppressor that regulates cellular oxygen sensing and proteostasis [1]. Canonically, VHL functions as the core substrate-recognition subunit of the Cullin2-RING E3 ubiquitin ligase complex (VCB-CR). Under physiological normoxia, VHL selectively binds to prolyl-hydroxylated hypoxia-inducible factor alpha (HIF-α), orchestrating its rapid proteasomal degradation. Conversely, loss or mutation of VHL leads to the stabilization of HIF-α, particularly HIF-2α [1]. The resulting constitutive stabilization of HIF-α initiates a “pseudohypoxic” transcriptional cascade, upregulating downstream effectors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) that promote pathological angiogenesis, metabolic reprogramming, tumor growth, and metastasis [1, 2]. The canonical VHL-HIF axis is central to the pathogenesis of clear cell renal cell carcinoma (ccRCC), where biallelic VHL inactivation—via somatic mutation, chromosomal 3p deletion, or epigenetic hypermethylation—serves as an early and central event in both hereditary and up to 80% of sporadic ccRCC cases [3, 4]. Importantly, VHL loss alone is insufficient for overt tumorigenesis. Malignant transformation typically requires cooperation with additional genetic alterations, particularly adjacent chromosome 3p tumor suppressors such as PBRM1, BAP1, and SETD2 [5–8]. While the traditional HIF-centric model alone cannot fully capture this multigenic complexity, VHL inactivation remains a foundational event across clones. Therefore, expanding the focus from VHL-HIF to the broader functional network offers a rational strategy to target this heterogeneous disease. Driven by this complex tumor biology [8, 9], RCC accounts for over 400,000 new global cases annually. As its predominant and most aggressive histological subtype, ccRCC representing approximately 70% of diagnoses [10, 11]. Advanced metastatic ccRCC maintains a 5-year overall survival (OS) rate of 8%-11.7%. This poor prognosis is compounded by high recurrence rate, as ~30% of surgical patients experiencing disease recurrence, often progressing to advanced stages characterized by limited therapeutic options [12, 13]. While targeting downstream of classical VHL-HIF pathway via tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has modified management strategies, treatment resistance remains a major limitation to long-term survival [12, 14]. The clinical development of belzutifan, a targeted HIF-2α inhibitor, expanded therapeutic options for VHL disease-associated tumors and pretreated advanced RCC [15]. Clinical responses, however, are heterogeneous rather than uniformly transient. In pretreated advanced ccRCC, a randomized phase III trial (LITESPARK-005) demonstrated an objective response rate (ORR) of 21.9% [16]. Conversely, long-term (50-month) phase II follow-up (LITESPARK-004) in VHL disease-associated RCC demonstrated an ORR of 67%, including 11% complete responses (CRs), and 59% patients remained on treatment [17]. These distinct populations should not be directly compared, but together they indicate that while resistance is not universal, intrinsic non-responsiveness and acquired disease progression remain principal clinical challenges [16–18]. Mechanistically, intrinsic resistance reflects variable tumor HIF dependence. Some VHL-deficient cell lines and xenograft models expressing little HIF-2α or lacking HIF-2-driven transcriptional programs fail to regress despite pharmacodynamic target suppression [19]. Inadequate drug exposure due to pharmacokinetic variability, dose reduction, or treatment-limiting toxicity should be distinguished from tumor-intrinsic resistance [20]. Moreover, intratumoral/interlesional heterogeneity, compensatory HIF-1 or alternative growth programs, and rare pre-existing resistant subclones may also contribute. Acquired resistance, by contrast, emerges after initial response or disease control via verified on-target mutations such as EPAS1/HIF-2α G323E and ARNT/HIF-1β F446L that disrupt drug binding (patient cohorts and preclinical models) or candidate bypass pathways [e.g., sustained CCND1/cyclin D1 signaling (preclinical models)] [21, 22]. Because much mechanistic data derives from early analogue molecules (PT2385/PT2399), direct longitudinal validation in belzutifan-treated patients remains limited. These gaps reinforce the need for predictive biomarkers and complementary HIF-independent strategies [23]. Novel target exploration and paradigm shift Historically, the understanding of VHL has been predominantly confined to its role in regulating HIF and consequent ccRCC pathogenesis. However, the inescapable therapeutic ceiling underscores a critical limitation: the HIF-centric model incompletely captures the complexity of VHL-related oncogenesis. In fact, the VHL-HIF axis represents only one facet of the complex tumor-suppressive network [24]. Therefore, mapping the expanding universe of non-HIF VHL novel targets has become clinical imperative, urgently required to dismantle entrenched resistance mechanisms and pioneer next-generation therapeutic modalities. This review provides an evidence-graded synthesis of non-canonical VHL targets, evaluating their biomarker utility and therapeutic applicability. We systematically delineate the expanding network of non-HIF targets across cellular processes. Then we broaden the ccRCC paradigm to evaluate VHL dysregulation across pan-cancer spectrum. Finally, we summary the research progress of small-molecule inhibitors (SMIs) targeting VHL novel targets and assess the dualistic utility of VHL within next-generation proteolysis-targeting chimeras (PROTACs) therapeutics. By synthesizing these advances of novel biomarkers and therapeutic avenues beyond traditional HIF inhibition, we aim to provide a rational framework to mitigate drug resistance and improve clinical outcomes across diverse VHL-related malignancies. The non-canonical VHL targets: functional modules & mechanisms High-throughput interactomics and functional genomics have identified a broad HIF-independent VHL network [25–29]. It is now unequivocally clear that VHL operates far beyond a singular oxygen-sensing switch; rather, it serves as a pleiotropic hub coordinating cellular homeostasis. To address mechanistic heterogeneity and ensure taxonomic precision, we stratify VHL-associated novel targets into four hierarchical classes: (1) E3 ligase substrates; (2) degradation-independent VHL-binding proteins; (3) VHL-stabilized or sterically shielded clients; and (4) VHL-associated downstream effectors or synthetic lethal partners. These interactions are organized into functional modules (Fig. 1). This comprehensive modular framework not only defines the multifaceted pathogenesis of VHL-associated malignancies but also exposes a rich landscape of context-dependent vulnerabilities for next-generation precision therapeutics (Table 1, Figures 2).Fig. 1The expanding mechanistic universe of VHL and its non-canonical targets. Pathogenic VHL dysfunction (center) radiates outward, systematically uncoupling eight distinct, HIF-independent functional modules. Arrow color and line styles denote the level of supporting evidence: blue solid arrows represent associations or pathways observed in human cohorts or observational datasets; black solid arrows indicate pathways validated by in vitro cell line, molecular, or biochemical experiments; purple solid arrows represent pathways validated by in vivo animal models or clinical trials; dashed arrows denote hypothesized pathways lacking direct experimental validation. Created with BioRender.com/b9mj5zqTable 1The research progress of VHL novel targetsNovel TargetsMode of VHL RegulationBiological Mechanism & VHL InteractionLevel of EvidenceThe Downstream Pathway of New TargetsBiomarker TypePotential Clinical ApplicationZHX2 [26, 30]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical validation; Cell lines & mouse xenografts; Independent patient cohorts.ZHX2 physically interacts with NF-κB p65 to drive profound oncogenic inflammatory signaling and transcription, conferring profound apoptotic resistance and anchorage-independent growth. ZHX2 drives cell growth and migration by transcriptionally activating the MEK/ERK1/2 signaling pathway. Accumulation of ZHX2 in VHL-deficient ccRCC promotes tumor growth and migration.Prognostic (Fuhrman grade, PFS).Predictive (Sunitinib resistance).Risk stratification for aggressive ccRCC; Potential target to overcome sunitinib resistance via autophagy inhibition.SFMBT1 [27]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation on Pro651 by EglN1 under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical validation (Pro651 hydroxylation); Cell lines & orthotopic mouse xenografts; Patient cohorts; Preclinical resistance models.SFMBT1–SPHK1 axis: Pathological accumulation of SFMBT1 in ccRCC drives the massive transcription of SPHK1, hyperactivating the sphingolipid/S1P metabolic survival pathway. SFMBT1 decisively skews the cellular “sphingolipid rheostat” toward malignant proliferation and robust angiogenesis via the family of S1PRs cascades.Prognostic (Poor OS, especially when co-elevated with ZHX2). Predictive (HIF-2α inhibitor and TKI resistance).Risk stratification for aggressive ccRCC. Targeting downstream S1P/SPHK1 axis to overcome HIF-2α inhibitor/TKI resistance.SETDB1 [25, 31, 32]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical interaction & hydroxylation assays; Cell lines & mouse xenografts; Patient cohort correlations.SETDB1-dsRNA/NF-κB/p53 signaling pathways: SETDB1 suppresses dsRNAs transcription by enforcing chromatin compaction, sterically occludes NF-κB recruitment by depositing H3K9me at pro-inflammatory promoters (e.g., IL-6), and suppresses p53/p21 via promoter H3K9 methylation. VHL loss induced SETDB1 stabilization suppresses anti-tumor immune responses, and increases tumor proliferation.Prognostic (Poor OS and immunosuppressive TME across cancers); Predictive (ICI resistance).Risk stratification; Pharmacological inhibition to trigger viral mimicry and sensitize VHL-mutant tumors to immunotherapy.METTL3/METTL14 [33]Degradation-independent VHL-binding/complex-assembly partnersVHL directly associates with METTL3/METTL14 and promotes writer-complex assembly without degrading either component.Co-IP and m6A quantification in RCC cell lines. 3D spheroids & orthotopic mouse models.VHL-METTL3/METTL14-m6A–IGF2BP1/2-PIK3R3–PI3K/AKT axis: VHL-dependent m6A modification enables IGF2BP1/2-mediated PIK3R3 mRNA stabilization. Consequently, VHL loss accelerates PIK3R3 transcript decay, releasing PI3K/AKT signaling to promote tumorigenesis in three-dimensional culture and orthotopic mouse models.Pharmacodynamic (Global m6A level serves as a surrogate marker for functional VHL scaffold activity). Predictive (Low PIK3R3 predicts sensitivity to PI3K/AKT or HIF-2α inhibitors).Monitoring cellular m6A levels as a surrogate pharmacodynamic readout for functional VHL scaffold activity. Low PIK3R3 levels select patients for PI3K/AKT or HIF-2α inhibitor therapy.FTO [34]VHL synthetic lethal partnerFTO inhibition selectively kills VHL-deficient cells by restoring m6A.Isogenic VHL cell lines. Subcutaneous mouse xenografts.Genetic or pharmacological inhibition of FTO selectively impairs VHL-deficient ccRCC growth in cell lines and xenografts by restoring m6A and suppressing SLC1A5-mediated glutamine transport.Predictive (VHL status as biomarker).Using VHL loss-of-function genomic status to stratify ccRCC patients for targeted FTO/metabolic inhibition regimens.RPB1 [35–37]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation on Pro1465 within the LGQLAP motif by PHD under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Biochemical assay (Pro1465); Cell lines & xenografts; ccRCC tissues.RPB1–CDC25A/CDK2/CCNA2 signaling pathway: In VHL-deficient malignancies, the failure to degrade RPB1 accelerating the unrestrained transcription of critical cell cycle engines. Paradoxically, hyper-hydroxylates RPB1 aggressively stimulates in vivo tumorigenesis by rewiring global transcriptional kinetics and selectively hyperactivating critical cell cycle engines (CDC25A, CDK2, CCNA2).Candidate diagnostic (Surrogate for VHL loss); Potential predictive (Cell-cycle/PHD1 therapy).Readout of functional VHL loss; Rationale for cell-cycle or PHD1-targeted therapies under oxidative stress.pRB [38–40]VHL E3 ligase substrate (Ubiquitin-mediated degradation)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical assay; Cell lines & mouse xenografts; Cross-species screens; ccRCC patient tissues.pRB-E2F/SKIDA1 signaling pathway: Driven by HIF-mediated cyclin D1 overexpression, hyperstabilized pRB becomes aberrantly hyperphosphorylated, neutralizing its E2F-sequestering capacity. It actively represses downstream tumor suppressors (SKIDA1) to sustain clonogenic survival and anchorage-independent growth in VHL-deficient ccRCC.Candidate diagnostic (Readout of functional VHL loss);Potential predictive (CDK4/6 inhibitor sensitivity).Assessment of functional VHL inactivation; Stratifying ccRCC patients for CDK4/6 inhibitor therapy.B-Myb [41]VHL E3 ligase substrate (Degradation blocked by Tyr15 phosphorylation)Degraded via the ubiquitin-proteasome pathway as a VHL substrate. RTK-mediated phosphorylation at Tyr15 prevents its degradation.Direct biochemical assays (Tyr15); Cell lines & mouse xenografts (No clinical cohorts).B-Myb-CFB/FKBP1B/SEPT6 signaling pathway: B-Myb regulates the expression of specific genes (CFB, FKBP1B, and SEPT6) to inhibit HIF-2α-dependent tumorigenesis. Knockdown of B-Myb accelerates tumor development in 786-O cells.Hypothetical Predictive (RTK/HIF-2α axis status).Conceptual basis for risk-stratifying ccRCC based on HIF-2α activity.EGFR [42, 43]VHL E3 ligase substrate (c-Cbl-independent degradation)VHL directly promotes the c-Cbl-independent polyubiquitylation of activated EGFR, routing the receptor toward proteasomal clearance.Cell lines (degradation); Patient tissue IHC in CNS hemangioblastomas (expression/cystic correlation).EGFR-Ras/MAPK & PI3K/AKT signaling pathways: The VHL-driven clearance serves as a fail-safe to acutely extinguish oncogenic cascades. Uncoupling this regulatory network traps hyperactive EGFR in early endosomes to amplify sustained mitogenic signaling. Unrestrained EGFR stabilization correlates with severe cystic expansion in VHL-associated CNS hemangioblastomas.Hypothetical Predictive (Associated with hemangioblastoma cystic development).Stratification of VHL-associated hemangioblastoma severity (Requires clinical validation).EPOR [44]VHL E3 ligase substrate (PHD3 hydroxylation-dependent at Pro419/Pro426)After hydroxylation on Pro419 and Pro426 by PHD3 under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.In vitro biochemical & cell line models (hydroxylation & degradation); Associated with VHL type 2C mutant phenotypes.EPOR-JAK2–STAT5 signaling pathway: VHL inactivation aberrantly stabilizes EPOR, unleashing constitutive downstream JAK2–STAT5 signaling, which is likely involved in the pathogenesis of specific tumor types seen in VHL disease, such as pheochromocytoma and hemangioblastoma.Potential diagnostic (Indicator of specific VHL disease sub-phenotypes).Sub-phenotypic stratification of VHL gene mutations (Requires clinical validation).Spry [45]VHL E3 ligase substrate (PHD1–3 hydroxylation-dependent at Pro18, Pro144, Pro160)Under normoxia, PHD1-3-mediated hydroxylation at three distinct proline residues (Pro18, 144, 160) licenses canonical VHL recognition, ubiquitination, and proteasomal clearance.In vitro biochemical & cell line assays (hydroxylation, ubiquitination & degradation).Spry2-FGF-ERK1/2 & c-Cbl pathways: Spry2 classically enhances the inhibition of FGF-elicited ERK1/2 activation, and its stabilization protects growth factor receptors from c-Cbl-mediated degradation. Pathologically stabilization in VHL-deficient carcinomas, fine-tuning growth factor responsiveness and oncogenic amplitude within the TME to contribute toward disease progression.Hypothetical predictive (Potential marker for ERK pathway responsiveness).Exploratory assessment of RTK/MAPK feedback dysregulation in ccRCC.AKT [46]Degradation-independent VHL-binding protein (EglN1/PHD2 hydroxylation-dependent binding at Pro125/Pro347)Upon normoxic, EglN1-mediated prolyl hydroxylation, AKT binds VHL, which directly recruits PP2AC to facilitate the targeted dephosphorylate and completely inactivation of AKT.Biochemistry, cell line & xenograft models (scaffolding & p-AKT hyperactivation); Clinical tissue cohort correlation (p-AKT with poor survival).PI3K/AKT/mTOR (PAM) signaling pathway: VHL loss dismantles PP2AC recruitment, and drives constitutive, HIF-independent hyperactivation of AKT and downstream mTOR, acting as a catalyst for aggressive proliferation, metabolic rewiring, and diminished clinical survival.Prognostic (Elevated p-AKT indicates aggressive disease & poor clinical outcome);Potential Predictive/Pharmacodynamic (Marker for PI3K/AKT/mTOR inhibitor sensitivity & target engagement).Risk stratification in ccRCC; Rational selection and monitoring for PI3K/AKT/mTOR pathway blockade (Requires clinical validation).NDRG3 [29, 47]VHL E3 ligase substrate (PHD2 hydroxylation-dependent normoxic degradation)Degraded via the EgIN3/VHL pathway under normoxia. Accumulation of intracellular lactate directly binds NDRG3, helping it evade VHL-mediated ubiquitination.Biochemistry, cell line & mouse xenograft assays (lactate-dependent stabilization, Raf-ERK activation, Syntaxin-5 interaction; HIF-1α feedback in PCa cell models).NDRG3-Raf-ERK/Syntaxin-5/HIF-1α pathways: Stabilized NDRG3 interacts with c-Raf to activate Raf-ERK, fueling aggressive angiogenesis, stemness, and targeted therapy resistance in therapy-resistant, chronically hypoxic malignancies. NDRG3 physically sequesters Syntaxin-5 to decelerate ER-to-Golgi transport. NDRG3 reduces hypoxic HIF-1α expression via inhibiting AKT-driven translation and dissociating the coactivator p300 from HIF-1α.Hypothetical prognostic (Indicator of chronic hypoxic adaptation and lactate-driven tumor aggressiveness); Hypothetical predictive (Potential marker for response to lactate/ERK pathway blockade).Molecular profiling of hypoxic/lactate-rich TME; Rationale for co-targeting lactate transport and downstream ERK signaling (Requires clinical validation).TFAM [48]Non-degradative protective binding protein/Stabilized clients (PHD3 hydroxylation-dependent binding at Pro53/Pro66)Following EglN3-mediated prolyl hydroxylation (Pro53/66), TFAM is bound by VHL, which competitively shields it from proteolytic destruction by LONP1.Biochemistry, cell line & mouse xenograft assays (PHD3 hydroxylation, VHL binding, LONP1 cleavage); Clinical tissue cohorts & TCGA analysis (low TFAM & mitochondrial depletion in ccRCC & pheochromocytoma).TFAM-mitochondrial DNA (mtDNA)/JNK/LCN2 signaling pathways: VHL inactivation unleashes unrestrained LONP1, which could eradicate TFAM, precipitating mitochondrial depletion in VHL-related tumors such as pheochromocytoma and ccRCC, halting mtDNA replication/transcription, and exacerbating ROS accumulation and inflammatory signaling (p-JNK, LCN2).Proposed diagnostic (Low TFAM & mitochondrial depletion indicate VHL loss and aggressive metabolic status); Potential predictive (Marker for LONP1 attenuation, TKI resensitization, & target engagement).Stratification of VHL-deficient tumors; Rationale for co-targeting LONP1 via bortezomib (a non-selective proteasome inhibitor) with TKIs (e.g., sorafenib) to overcome metabolic resistance (Requires clinical validation).Fibronectin [49, 50]Degradation-independent VHL-binding protein/Matrix assembly client (Requires VHL for physical interaction and pericellular matrix assembly)VHL physically interacts with fibronectin in vivo under physiological conditions. VHL also upregulates it at a transcriptional level and in a hypoxia-independent way.Biochemical co-IP, cell line & mouse xenograft assays (VHL-fibronectin interaction, ECM assembly assays; HIF-independent transcription); Human ccRCC tissue/cohort correlation (Fibronectin matrix disruption in VHL-mutant RCC).Fibronectin-ECM interaction: VHL physically interacts with fibronectin in vivo under physiological conditions, and that this interaction affects the ability of cells to assemble an ECM. Normal Fibronectin function can suppress metastasis by enhancing the interaction between tumor cells and their microenvironment, and reverse malignant phenotypes by inhibiting proliferation and migration.Proposed diagnostic/predictive (Loss of pericellular fibronectin matrix assembly indicates VHL mutation, ECM destabilization, and invasive risk in ccRCC).Histological assessment of tumor ECM matrix integrity for ccRCC characterization; Evaluation of invasive and metastatic potential in VHL-deficient malignancies.COL4A2 [51, 52]Degradation-independent VHL-binding protein/Matrix assembly client (ER prolyl hydroxylation-dependent binding to unfolded N-terminus)VHL physically binds to the unfolded N-terminal tail of the COL4A2 chain (requiring ER-mediated prolyl hydroxylation, independent of HIF).Biochemical co-IP & ER hydroxylation binding assays; Cell line & mouse xenograft assays (collagen matrix assembly, invasion, angiogenesis); Human ccRCC tissue correlation.VHL-COL4A2 ECM assembly pathway: VHL-COL4A2 tethering is indispensable for the proper supramolecular collagen IV network assembly. Abrogation of VHL-COL4A2 binding structurally dismantles the ECM, generating a mechanically permissive TME that actively licenses unbridled vascular infiltration, pathogenic angiogenesis, and aggressive invasion in ccRCC.Proposed diagnostic (Loss of collagen IV matrix integrity indicates VHL loss, type 2C variant status, basement membrane degradation & invasive risk).Stratification of VHL mutation types (including HIF-competent type 2C mutants); Assessment of basement membrane stability and metastatic risk in ccRCC (Requires clinical validation).AURKA [53–55]Non-canonical VHL E3 ligase substrate (PHD-independent multi-monoubiquitination/degradation)VHL executes a direct, PHD-independent multi-monoubiquitination of AURKA for degradation. VHL ablation provokes an indirect, secondary HIF-dependent transcriptional surge of AURKA and NEDD9.Biochemistry & ubiquitination/phosphorylation assays; Cell line & mouse xenograft assays (ciliary axoneme disassembly, cell motility, AURKA/HDAC6 inhibitor rescue); Human ccRCC tissue correlation.VHL-AURKA-HDAC6 signaling axis: Convergent loss of VHL unleashes massive AURKA hyperactivation, which aggressively drives HDAC6-mediated tubulin depolymerization, effectively dismantling the ciliary axoneme, driving renal cystogenesis, and promoting motility and metastasis in early-stage VHL-associated ciliopathies and advanced ccRCC.Proposed diagnostic (AURKA elevation and primary cilia loss indicate VHL mutation, renal cystogenesis).Stratification of VHL-driven ciliopathies and aggressive ccRCC. Rationale for targeted AURKA (e.g., alisertib) or HDAC6 inhibition to restore primary ciliation (Requires clinical validation).aPKC [56, 57]Degradation-independent VHL-binding protein/E3 ligase client (non-degradative ubiquitination)VHL exerts direct, degradation-independent control by selectively ubiquitinating the active, phosphorylated isoform of aPKC.Biochemical co-IP & in vitro ubiquitination assays; RCC cell line assays (cell polarity, tight junction maintenance, endo-lysosomal α5 integrin degradation).VHL- microtubule -aPKC-α5 integrin pathway: VHL-PKCι complex actively anchors aPKC to the membrane to maintain microtubule stability/cell polarity, and orchestrates the endo-lysosomal internalization and clearance of pro-metastatic α5 integrin. VHL ablation uncouples the VHL-aPKC spatio-biochemical hub, simultaneously dismantling tight junctions, hyperactivating α5 integrin-driven tissue invasion to facilitate aggressive tissue invasion, and provoking a compensatory, PKCι-driven surge in HIF-α in RCC.Proposed diagnostic/predictive (aPKC hyperactivation/mislocalization and α5 integrin accumulation indicate VHL loss, polarity disruption, & invasive RCC risk).Assessment of epithelial polarity integrity and invasive potential in RCC; Exploration of aPKC signaling or integrin trafficking blockade.TBK1 [28, 58]Degradation-independent VHL-binding protein/Synthetic lethal partner (EglN1 Pro48 hydroxylation-dependent binding)After hydroxylation on Pro48 by EgIN1 under normoxia, it binds to VHL, which recuits PPM1B to dephosphorylate and inactivate TBK1.Direct co-IP & PPM1B phosphatase recruitment assays; CRISPR synthetic lethal screens; Mouse xenograft models (p62 phosphorylation, autophagic flux, tumor growth).TBK1-p62 autophagy signaling pathway: TBK1 is subverted into an autophagy modulator and tumorigenesis promoter upon VHL loss. Hyperactivated TBK1 phosphorylates p62 at Ser366, which facilitates the degradation of specific proteins by modulating pro-tumorigenic autophagy signaling, and promotes cell proliferation and xenograft ccRCC growth.Proposed predictive (Elevated phospho-TBK1 and VHL loss predict responsiveness to synthetic lethal TBK1 inhibitors).Potential therapeutic target to overcome immune evasion via synthetic lethal sensitivity of TBK1 targeted inhibition.RIPK1 [59]Degradation-independent VHL-binding protein/Kinase inhibitor client (EglN1 prolyl hydroxylation-dependent binding)After hydroxylation by EgIN1, VHL directly binds hydroxylated RIPK1 to suppress Ser166 kinase autophosphorylation.Direct biochemical co-IP & in vitro kinase assays; Cell lines (necroptosis vs. apoptosis, sunitinib resistance); Mouse tumor models (ARG1+ myeloid TME infiltration, ICIs resistance).RIPK1-TNF/NF-κB/Chemokine pathways: RIPK1 intrinsically subverts TNF signaling away from CASP8-dependent apoptosis and toward NF-κB-driven survival. This cell-intrinsic rewiring orchestrates a immunosuppressive chemokine program. O-GlcNAcylation of RIPK1 induces sunitinib resistance in RCC by inhibiting RIPK-dependent apoptosis.Proposed predictive (Elevated p-RIPK1 or O-GlcNAcylation predicts resistance to ICIs and sunitinib, as well as sensitivity to RIPK1 inhibitors).Patient stratification for ICIs and sunitinib response; Therapeutic combinations targeting RIPK1 to overcome immune evasion and restore ICI/TKI sensitivity (Requires clinical validation).UBE3B [60]Non-canonical VHL E3 ligase substrate (O2/hydroxylation-independent)VHL β-domain physically engages UBE3B (oxygen-independent), driving its K48-linked polyubiquitination specifically at K286 and K427 to enforce rapid proteasomal clearance.Direct co-IP, in vitro binding & ubiquitination assays; Breast cancer cell line models (HIF-2α stabilization, invasion); Mouse tumor xenograft & lung metastasis models; Human breast cancer tissue cohorts.UBE3B-HIF-2α signaling pathway: UBE3B accumulates upon VHL ablation, unleashing aggressive tumor proliferation and lung metastasis. In addition, UBE3B functions as a oxygen-independent stabilizer of HIF-2α, actively shielding HIF-2α from VHL-mediated degradation.Predictive & prognostic (Elevated UBE3B expression or inverse VHL/UBE3B ratio correlates with increased risk of pulmonary metastasis and poor OS).Prognostic biomarker for breast cancer and predictive biomarker for metastatic risk. Potential therapeutic target to dismantle VHL-independent HIF-2α hyperactivation.JADE1 [61–64]Non-degradative protective binding protein/Stabilized clients (VHL β-domain binds JADE1 and α-domain stabilizes it)VHL acts as a critical stabilizing chaperone. VHL binding requires its β-domain, while JADE1 stabilization is strictly dependent on the intact VHL α-domain (abrogated by L118P/R167W mutations).Direct co-IP, binding domain mapping, and structural dynamics modeling. In vitro RCC cell line models (ubiquitination & AKT binding/inhibition). Genotype-phenotype correlation.JADE1-β-catenin & AKT signaling pathways: Stabilized JADE1 operates as a non-canonical E3 ligase to indiscriminately ubiquitylate β-catenin (suppressing Wnt signaling) and suppresses active phospho-AKT1. VHL ablation precipitates JADE1 depletion, unleashing a dual oncogenic surge of unrestrained β-catenin-driven proliferation and superactivated AKT signaling.Prognostic (Downregulated JADE1 protein expression correlates with advanced histologic grade, aggressive ccRCC features, and poor survival).Prognostic risk stratification in ccRCC. Biomarker-guided selection for targeted therapies co-inhibiting Wnt/β-catenin and PI3K/AKT pathways.BIM-EL [65, 66]Non-degradative protective binding protein/VHL-stabilized clients (sterically shielded)Following EglN3-dependent prolyl hydroxylation at Pro67 and Pro70, VHL physically binds BIM-EL, sterically shielding Ser69 from ERK-driven phosphorylation to rescue it from proteasomal destruction.Direct co-IP, binding domain mapping, in vitro phosphorylation assays. Cell lines (sympathoadrenal cell apoptosis, RCC chemoresistance to cisplatin, ERK inhibitor restoration). Genotype-phenotype correlation.BIM-EL-ERK/Apoptotic signaling pathway: Unrestrained ERK-driven phosphorylation leads to proteasomal destruction of the pro-apoptotic BIM-EL, which permits sympathoadrenal lineage cells to evade developmental apoptosis. In advanced ccRCC, this VHL ablation-induced BIM-EL depletion confers enhanced cell survival and innate resistance to DNA-damaging chemotherapeutics.Proposed predictive (Decreased BIM-EL expression predicts resistance to conventional chemotherapy and sensitivity to MEK/ERK inhibitor combinations). Potential diagnostic (Distinguishing type 2C pheochromocytoma/paraganglioma).Patient stratification for chemotherapy sensitivity in VHL-deficient cancers. Biomarker-guided combination therapy using MEK/ERK inhibitors to restore BIM-EL stability and sensitize tumors to apoptosis.nCLU [67]Direct non-proteolytic E3 ligase substrate/VHL-associated downstream effectors (K63-linked polyubiquitination)VHL physically engages nCLU directly at its β-domain and specifically catalyzes the K63-linked polyubiquitination of nCLU.Direct co-IP, biochemical mapping, in vitro ubiquitination assays; cell line models (nucleocytoplasmic trafficking); Human RCC tissue IHC and cell culture supernatant analysis.nCLU nucleocytoplasmic translocation signaling: The precise K63-linked ubiquitin topology serves strictly as a spatial localization signal and induces distinct cellular morphological alterations without necessarily triggering apoptosis, actively driving the nucleocytoplasmic translocation of nCLU.Potential diagnostic (Altered clusterin subcellular localization or secretory level correlates with VHL functional inactivation independently of HIF-α accumulation).Potential tissue IHC or fluid-based surrogate biomarker for assessing HIF-independent VHL functional loss in RCC. The expanding mechanistic universe of VHL and its non-canonical targets. Pathogenic VHL dysfunction (center) radiates outward, systematically uncoupling eight distinct, HIF-independent functional modules. Arrow color and line styles denote the level of supporting evidence: blue solid arrows represent associations or pathways observed in human cohorts or observational datasets; black solid arrows indicate pathways validated by in vitro cell line, molecular, or biochemical experiments; purple solid arrows represent pathways validated by in vivo animal models or clinical trials; dashed arrows denote hypothesized pathways lacking direct experimental validation. Created with BioRender.com/b9mj5zq Table 1The research progress of VHL novel targetsNovel TargetsMode of VHL RegulationBiological Mechanism & VHL InteractionLevel of EvidenceThe Downstream Pathway of New TargetsBiomarker TypePotential Clinical ApplicationZHX2 [26, 30]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical validation; Cell lines & mouse xenografts; Independent patient cohorts.ZHX2 physically interacts with NF-κB p65 to drive profound oncogenic inflammatory signaling and transcription, conferring profound apoptotic resistance and anchorage-independent growth. ZHX2 drives cell growth and migration by transcriptionally activating the MEK/ERK1/2 signaling pathway. Accumulation of ZHX2 in VHL-deficient ccRCC promotes tumor growth and migration.Prognostic (Fuhrman grade, PFS).Predictive (Sunitinib resistance).Risk stratification for aggressive ccRCC; Potential target to overcome sunitinib resistance via autophagy inhibition.SFMBT1 [27]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation on Pro651 by EglN1 under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical validation (Pro651 hydroxylation); Cell lines & orthotopic mouse xenografts; Patient cohorts; Preclinical resistance models.SFMBT1–SPHK1 axis: Pathological accumulation of SFMBT1 in ccRCC drives the massive transcription of SPHK1, hyperactivating the sphingolipid/S1P metabolic survival pathway. SFMBT1 decisively skews the cellular “sphingolipid rheostat” toward malignant proliferation and robust angiogenesis via the family of S1PRs cascades.Prognostic (Poor OS, especially when co-elevated with ZHX2). Predictive (HIF-2α inhibitor and TKI resistance).Risk stratification for aggressive ccRCC. Targeting downstream S1P/SPHK1 axis to overcome HIF-2α inhibitor/TKI resistance.SETDB1 [25, 31, 32]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical interaction & hydroxylation assays; Cell lines & mouse xenografts; Patient cohort correlations.SETDB1-dsRNA/NF-κB/p53 signaling pathways: SETDB1 suppresses dsRNAs transcription by enforcing chromatin compaction, sterically occludes NF-κB recruitment by depositing H3K9me at pro-inflammatory promoters (e.g., IL-6), and suppresses p53/p21 via promoter H3K9 methylation. VHL loss induced SETDB1 stabilization suppresses anti-tumor immune responses, and increases tumor proliferation.Prognostic (Poor OS and immunosuppressive TME across cancers); Predictive (ICI resistance).Risk stratification; Pharmacological inhibition to trigger viral mimicry and sensitize VHL-mutant tumors to immunotherapy.METTL3/METTL14 [33]Degradation-independent VHL-binding/complex-assembly partnersVHL directly associates with METTL3/METTL14 and promotes writer-complex assembly without degrading either component.Co-IP and m6A quantification in RCC cell lines. 3D spheroids & orthotopic mouse models.VHL-METTL3/METTL14-m6A–IGF2BP1/2-PIK3R3–PI3K/AKT axis: VHL-dependent m6A modification enables IGF2BP1/2-mediated PIK3R3 mRNA stabilization. Consequently, VHL loss accelerates PIK3R3 transcript decay, releasing PI3K/AKT signaling to promote tumorigenesis in three-dimensional culture and orthotopic mouse models.Pharmacodynamic (Global m6A level serves as a surrogate marker for functional VHL scaffold activity). Predictive (Low PIK3R3 predicts sensitivity to PI3K/AKT or HIF-2α inhibitors).Monitoring cellular m6A levels as a surrogate pharmacodynamic readout for functional VHL scaffold activity. Low PIK3R3 levels select patients for PI3K/AKT or HIF-2α inhibitor therapy.FTO [34]VHL synthetic lethal partnerFTO inhibition selectively kills VHL-deficient cells by restoring m6A.Isogenic VHL cell lines. Subcutaneous mouse xenografts.Genetic or pharmacological inhibition of FTO selectively impairs VHL-deficient ccRCC growth in cell lines and xenografts by restoring m6A and suppressing SLC1A5-mediated glutamine transport.Predictive (VHL status as biomarker).Using VHL loss-of-function genomic status to stratify ccRCC patients for targeted FTO/metabolic inhibition regimens.RPB1 [35–37]VHL E3 ligase substrate (Hydroxylation-dependent)After hydroxylation on Pro1465 within the LGQLAP motif by PHD under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Biochemical assay (Pro1465); Cell lines & xenografts; ccRCC tissues.RPB1–CDC25A/CDK2/CCNA2 signaling pathway: In VHL-deficient malignancies, the failure to degrade RPB1 accelerating the unrestrained transcription of critical cell cycle engines. Paradoxically, hyper-hydroxylates RPB1 aggressively stimulates in vivo tumorigenesis by rewiring global transcriptional kinetics and selectively hyperactivating critical cell cycle engines (CDC25A, CDK2, CCNA2).Candidate diagnostic (Surrogate for VHL loss); Potential predictive (Cell-cycle/PHD1 therapy).Readout of functional VHL loss; Rationale for cell-cycle or PHD1-targeted therapies under oxidative stress.pRB [38–40]VHL E3 ligase substrate (Ubiquitin-mediated degradation)After hydroxylation by PHD, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.Direct biochemical assay; Cell lines & mouse xenografts; Cross-species screens; ccRCC patient tissues.pRB-E2F/SKIDA1 signaling pathway: Driven by HIF-mediated cyclin D1 overexpression, hyperstabilized pRB becomes aberrantly hyperphosphorylated, neutralizing its E2F-sequestering capacity. It actively represses downstream tumor suppressors (SKIDA1) to sustain clonogenic survival and anchorage-independent growth in VHL-deficient ccRCC.Candidate diagnostic (Readout of functional VHL loss);Potential predictive (CDK4/6 inhibitor sensitivity).Assessment of functional VHL inactivation; Stratifying ccRCC patients for CDK4/6 inhibitor therapy.B-Myb [41]VHL E3 ligase substrate (Degradation blocked by Tyr15 phosphorylation)Degraded via the ubiquitin-proteasome pathway as a VHL substrate. RTK-mediated phosphorylation at Tyr15 prevents its degradation.Direct biochemical assays (Tyr15); Cell lines & mouse xenografts (No clinical cohorts).B-Myb-CFB/FKBP1B/SEPT6 signaling pathway: B-Myb regulates the expression of specific genes (CFB, FKBP1B, and SEPT6) to inhibit HIF-2α-dependent tumorigenesis. Knockdown of B-Myb accelerates tumor development in 786-O cells.Hypothetical Predictive (RTK/HIF-2α axis status).Conceptual basis for risk-stratifying ccRCC based on HIF-2α activity.EGFR [42, 43]VHL E3 ligase substrate (c-Cbl-independent degradation)VHL directly promotes the c-Cbl-independent polyubiquitylation of activated EGFR, routing the receptor toward proteasomal clearance.Cell lines (degradation); Patient tissue IHC in CNS hemangioblastomas (expression/cystic correlation).EGFR-Ras/MAPK & PI3K/AKT signaling pathways: The VHL-driven clearance serves as a fail-safe to acutely extinguish oncogenic cascades. Uncoupling this regulatory network traps hyperactive EGFR in early endosomes to amplify sustained mitogenic signaling. Unrestrained EGFR stabilization correlates with severe cystic expansion in VHL-associated CNS hemangioblastomas.Hypothetical Predictive (Associated with hemangioblastoma cystic development).Stratification of VHL-associated hemangioblastoma severity (Requires clinical validation).EPOR [44]VHL E3 ligase substrate (PHD3 hydroxylation-dependent at Pro419/Pro426)After hydroxylation on Pro419 and Pro426 by PHD3 under normoxia, it is ubiquitinated by VHL and finally degraded by the 26S proteasome.In vitro biochemical & cell line models (hydroxylation & degradation); Associated with VHL type 2C mutant phenotypes.EPOR-JAK2–STAT5 signaling pathway: VHL inactivation aberrantly stabilizes EPOR, unleashing constitutive downstream JAK2–STAT5 signaling, which is likely involved in the pathogenesis of specific tumor types seen in VHL disease, such as pheochromocytoma and hemangioblastoma.Potential diagnostic (Indicator of specific VHL disease sub-phenotypes).Sub-phenotypic stratification of VHL gene mutations (Requires clinical validation).Spry [45]VHL E3 ligase substrate (PHD1–3 hydroxylation-dependent at Pro18, Pro144, Pro160)Under normoxia, PHD1-3-mediated hydroxylation at three distinct proline residues (Pro18, 144, 160) licenses canonical VHL recognition, ubiquitination, and proteasomal clearance.In vitro biochemical & cell line assays (hydroxylation, ubiquitination & degradation).Spry2-FGF-ERK1/2 & c-Cbl pathways: Spry2 classically enhances the inhibition of FGF-elicited ERK1/2 activation, and its stabilization protects growth factor receptors from c-Cbl-mediated degradation. Pathologically stabilization in VHL-deficient carcinomas, fine-tuning growth factor responsiveness and oncogenic amplitude within the TME to contribute toward disease progression.Hypothetical predictive (Potential marker for ERK pathway responsiveness).Exploratory assessment of RTK/MAPK feedback dysregulation in ccRCC.AKT [46]Degradation-independent VHL-binding protein (EglN1/PHD2 hydroxylation-dependent binding at Pro125/Pro347)Upon normoxic, EglN1-mediated prolyl hydroxylation, AKT binds VHL, which directly recruits PP2AC to facilitate the targeted dephosphorylate and completely inactivation of AKT.Biochemistry, cell line & xenograft models (scaffolding & p-AKT hyperactivation); Clinical tissue cohort correlation (p-AKT with poor survival).PI3K/AKT/mTOR (PAM) signaling pathway: VHL loss dismantles PP2AC recruitment, and drives constitutive, HIF-independent hyperactivation of AKT and downstream mTOR, acting as a catalyst for aggressive proliferation, metabolic rewiring, and diminished clinical survival.Prognostic (Elevated p-AKT indicates aggressive disease & poor clinical outcome);Potential Predictive/Pharmacodynamic (Marker for PI3K/AKT/mTOR inhibitor sensitivity & target engagement).Risk stratification in ccRCC; Rational selection and monitoring for PI3K/AKT/mTOR pathway blockade (Requires clinical validation).NDRG3 [29, 47]VHL E3 ligase substrate (PHD2 hydroxylation-dependent normoxic degradation)Degraded via the EgIN3/VHL pathway under normoxia. Accumulation of intracellular lactate directly binds NDRG3, helping it evade VHL-mediated ubiquitination.Biochemistry, cell line & mouse xenograft assays (lactate-dependent stabilization, Raf-ERK activation, Syntaxin-5 interaction; HIF-1α feedback in PCa cell models).NDRG3-Raf-ERK/Syntaxin-5/HIF-1α pathways: Stabilized NDRG3 interacts with c-Raf to activate Raf-ERK, fueling aggressive angiogenesis, stemness, and targeted therapy resistance in therapy-resistant, chronically hypoxic malignancies. NDRG3 physically sequesters Syntaxin-5 to decelerate ER-to-Golgi transport. NDRG3 reduces hypoxic HIF-1α expression via inhibiting AKT-driven translation and dissociating the coactivator p300 from HIF-1α.Hypothetical prognostic (Indicator of chronic hypoxic adaptation and lactate-driven tumor aggressiveness); Hypothetical predictive (Potential marker for response to lactate/ERK pathway blockade).Molecular profiling of hypoxic/lactate-rich TME; Rationale for co-targeting lactate transport and downstream ERK signaling (Requires clinical validation).TFAM [48]Non-degradative protective binding protein/Stabilized clients (PHD3 hydroxylation-dependent binding at Pro53/Pro66)Following EglN3-mediated prolyl hydroxylation (Pro53/66), TFAM is bound by VHL, which competitively shields it from proteolytic destruction by LONP1.Biochemistry, cell line & mouse xenograft assays (PHD3 hydroxylation, VHL binding, LONP1 cleavage); Clinical tissue cohorts & TCGA analysis (low TFAM & mitochondrial depletion in ccRCC & pheochromocytoma).TFAM-mitochondrial DNA (mtDNA)/JNK/LCN2 signaling pathways: VHL inactivation unleashes unrestrained LONP1, which could eradicate TFAM, precipitating mitochondrial depletion in VHL-related tumors such as pheochromocytoma and ccRCC, halting mtDNA replication/transcription, and exacerbating ROS accumulation and inflammatory signaling (p-JNK, LCN2).Proposed diagnostic (Low TFAM & mitochondrial depletion indicate VHL loss and aggressive metabolic status); Potential predictive (Marker for LONP1 attenuation, TKI resensitization, & target engagement).Stratification of VHL-deficient tumors; Rationale for co-targeting LONP1 via bortezomib (a non-selective proteasome inhibitor) with TKIs (e.g., sorafenib) to overcome metabolic resistance (Requires clinical validation).Fibronectin [49, 50]Degradation-independent VHL-binding protein/Matrix assembly client (Requires VHL for physical interaction and pericellular matrix assembly)VHL physically interacts with fibronectin in vivo under physiological conditions. VHL also upregulates it at a transcriptional level and in a hypoxia-independent way.Biochemical co-IP, cell line & mouse xenograft assays (VHL-fibronectin interaction, ECM assembly assays; HIF-independent transcription); Human ccRCC tissue/cohort correlation (Fibronectin matrix disruption in VHL-mutant RCC).Fibronectin-ECM interaction: VHL physically interacts with fibronectin in vivo under physiological conditions, and that this interaction affects the ability of cells to assemble an ECM. Normal Fibronectin function can suppress metastasis by enhancing the interaction between tumor cells and their microenvironment, and reverse malignant phenotypes by inhibiting proliferation and migration.Proposed diagnostic/predictive (Loss of pericellular fibronectin matrix assembly indicates VHL mutation, ECM destabilization, and invasive risk in ccRCC).Histological assessment of tumor ECM matrix integrity for ccRCC characterization; Evaluation of invasive and metastatic potential in VHL-deficient malignancies.COL4A2 [51, 52]Degradation-independent VHL-binding protein/Matrix assembly client (ER prolyl hydroxylation-dependent binding to unfolded N-terminus)VHL physically binds to the unfolded N-terminal tail of the COL4A2 chain (requiring ER-mediated prolyl hydroxylation, independent of HIF).Biochemical co-IP & ER hydroxylation binding assays; Cell line & mouse xenograft assays (collagen matrix assembly, invasion, angiogenesis); Human ccRCC tissue correlation.VHL-COL4A2 ECM assembly pathway: VHL-COL4A2 tethering is indispensable for the proper supramolecular collagen IV network assembly. Abrogation of VHL-COL4A2 binding structurally dismantles the ECM, generating a mechanically permissive TME that actively licenses unbridled vascular infiltration, pathogenic angiogenesis, and aggressive invasion in ccRCC.Proposed diagnostic (Loss of collagen IV matrix integrity indicates VHL loss, type 2C variant status, basement membrane degradation & invasive risk).Stratification of VHL mutation types (including HIF-competent type 2C mutants); Assessment of basement membrane stability and metastatic risk in ccRCC (Requires clinical validation).AURKA [53–55]Non-canonical VHL E3 ligase substrate (PHD-independent multi-monoubiquitination/degradation)VHL executes a direct, PHD-independent multi-monoubiquitination of AURKA for degradation. VHL ablation provokes an indirect, secondary HIF-dependent transcriptional surge of AURKA and NEDD9.Biochemistry & ubiquitination/phosphorylation assays; Cell line & mouse xenograft assays (ciliary axoneme disassembly, cell motility, AURKA/HDAC6 inhibitor rescue); Human ccRCC tissue correlation.VHL-AURKA-HDAC6 signaling axis: Convergent loss of VHL unleashes massive AURKA hyperactivation, which aggressively drives HDAC6-mediated tubulin depolymerization, effectively dismantling the ciliary axoneme, driving renal cystogenesis, and promoting motility and metastasis in early-stage VHL-associated ciliopathies and advanced ccRCC.Proposed diagnostic (AURKA elevation and primary cilia loss indicate VHL mutation, renal cystogenesis).Stratification of VHL-driven ciliopathies and aggressive ccRCC. Rationale for targeted AURKA (e.g., alisertib) or HDAC6 inhibition to restore primary ciliation (Requires clinical validation).aPKC [56, 57]Degradation-independent VHL-binding protein/E3 ligase client (non-degradative ubiquitination)VHL exerts direct, degradation-independent control by selectively ubiquitinating the active, phosphorylated isoform of aPKC.Biochemical co-IP & in vitro ubiquitination assays; RCC cell line assays (cell polarity, tight junction maintenance, endo-lysosomal α5 integrin degradation).VHL- microtubule -aPKC-α5 integrin pathway: VHL-PKCι complex actively anchors aPKC to the membrane to maintain microtubule stability/cell polarity, and orchestrates the endo-lysosomal internalization and clearance of pro-metastatic α5 integrin. VHL ablation uncouples the VHL-aPKC spatio-biochemical hub, simultaneously dismantling tight junctions, hyperactivating α5 integrin-driven tissue invasion to facilitate aggressive tissue invasion, and provoking a compensatory, PKCι-driven surge in HIF-α in RCC.Proposed diagnostic/predictive (aPKC hyperactivation/mislocalization and α5 integrin accumulation indicate VHL loss, polarity disruption, & invasive RCC risk).Assessment of epithelial polarity integrity and invasive potential in RCC; Exploration of aPKC signaling or integrin trafficking blockade.TBK1 [28, 58]Degradation-independent VHL-binding protein/Synthetic lethal partner (EglN1 Pro48 hydroxylation-dependent binding)After hydroxylation on Pro48 by EgIN1 under normoxia, it binds to VHL, which recuits PPM1B to dephosphorylate and inactivate TBK1.Direct co-IP & PPM1B phosphatase recruitment assays; CRISPR synthetic lethal screens; Mouse xenograft models (p62 phosphorylation, autophagic flux, tumor growth).TBK1-p62 autophagy signaling pathway: TBK1 is subverted into an autophagy modulator and tumorigenesis promoter upon VHL loss. Hyperactivated TBK1 phosphorylates p62 at Ser366, which facilitates the degradation of specific proteins by modulating pro-tumorigenic autophagy signaling, and promotes cell proliferation and xenograft ccRCC growth.Proposed predictive (Elevated phospho-TBK1 and VHL loss predict responsiveness to synthetic lethal TBK1 inhibitors).Potential therapeutic target to overcome immune evasion via synthetic lethal sensitivity of TBK1 targeted inhibition.RIPK1 [59]Degradation-independent VHL-binding protein/Kinase inhibitor client (EglN1 prolyl hydroxylation-dependent binding)After hydroxylation by EgIN1, VHL directly binds hydroxylated RIPK1 to suppress Ser166 kinase autophosphorylation.Direct biochemical co-IP & in vitro kinase assays; Cell lines (necroptosis vs. apoptosis, sunitinib resistance); Mouse tumor models (ARG1+ myeloid TME infiltration, ICIs resistance).RIPK1-TNF/NF-κB/Chemokine pathways: RIPK1 intrinsically subverts TNF signaling away from CASP8-dependent apoptosis and toward NF-κB-driven survival. This cell-intrinsic rewiring orchestrates a immunosuppressive chemokine program. O-GlcNAcylation of RIPK1 induces sunitinib resistance in RCC by inhibiting RIPK-dependent apoptosis.Proposed predictive (Elevated p-RIPK1 or O-GlcNAcylation predicts resistance to ICIs and sunitinib, as well as sensitivity to RIPK1 inhibitors).Patient stratification for ICIs and sunitinib response; Therapeutic combinations targeting RIPK1 to overcome immune evasion and restore ICI/TKI sensitivity (Requires clinical validation).UBE3B [60]Non-canonical VHL E3 ligase substrate (O2/hydroxylation-independent)VHL β-domain physically engages UBE3B (oxygen-independent), driving its K48-linked polyubiquitination specifically at K286 and K427 to enforce rapid proteasomal clearance.Direct co-IP, in vitro binding & ubiquitination assays; Breast cancer cell line models (HIF-2α stabilization, invasion); Mouse tumor xenograft & lung metastasis models; Human breast cancer tissue cohorts.UBE3B-HIF-2α signaling pathway: UBE3B accumulates upon VHL ablation, unleashing aggressive tumor proliferation and lung metastasis. In addition, UBE3B functions as a oxygen-independent stabilizer of HIF-2α, actively shielding HIF-2α from VHL-mediated degradation.Predictive & prognostic (Elevated UBE3B expression or inverse VHL/UBE3B ratio correlates with increased risk of pulmonary metastasis and poor OS).Prognostic biomarker for breast cancer and predictive biomarker for metastatic risk. Potential therapeutic target to dismantle VHL-independent HIF-2α hyperactivation.JADE1 [61–64]Non-degradative protective binding protein/Stabilized clients (VHL β-domain binds JADE1 and α-domain stabilizes it)VHL acts as a critical stabilizing chaperone. VHL binding requires its β-domain, while JADE1 stabilization is strictly dependent on the intact VHL α-domain (abrogated by L118P/R167W mutations).Direct co-IP, binding domain mapping, and structural dynamics modeling. In vitro RCC cell line models (ubiquitination & AKT binding/inhibition). Genotype-phenotype correlation.JADE1-β-catenin & AKT signaling pathways: Stabilized JADE1 operates as a non-canonical E3 ligase to indiscriminately ubiquitylate β-catenin (suppressing Wnt signaling) and suppresses active phospho-AKT1. VHL ablation precipitates JADE1 depletion, unleashing a dual oncogenic surge of unrestrained β-catenin-driven proliferation and superactivated AKT signaling.Prognostic (Downregulated JADE1 protein expression correlates with advanced histologic grade, aggressive ccRCC features, and poor survival).Prognostic risk stratification in ccRCC. Biomarker-guided selection for targeted therapies co-inhibiting Wnt/β-catenin and PI3K/AKT pathways.BIM-EL [65, 66]Non-degradative protective binding protein/VHL-stabilized clients (sterically shielded)Following EglN3-dependent prolyl hydroxylation at Pro67 and Pro70, VHL physically binds BIM-EL, sterically shielding Ser69 from ERK-driven phosphorylation to rescue it from proteasomal destruction.Direct co-IP, binding domain mapping, in vitro phosphorylation assays. Cell lines (sympathoadrenal cell apoptosis, RCC chemoresistance to cisplatin, ERK inhibitor restoration). Genotype-phenotype correlation.BIM-EL-ERK/Apoptotic signaling pathway: Unrestrained ERK-driven phosphorylation leads to proteasomal destruction of the pro-apoptotic BIM-EL, which permits sympathoadrenal lineage cells to evade developmental apoptosis. In advanced ccRCC, this VHL ablation-induced BIM-EL depletion confers enhanced cell survival and innate resistance to DNA-damaging chemotherapeutics.Proposed predictive (Decreased BIM-EL expression predicts resistance to conventional chemotherapy and sensitivity to MEK/ERK inhibitor combinations). Potential diagnostic (Distinguishing type 2C pheochromocytoma/paraganglioma).Patient stratification for chemotherapy sensitivity in VHL-deficient cancers. Biomarker-guided combination therapy using MEK/ERK inhibitors to restore BIM-EL stability and sensitize tumors to apoptosis.nCLU [67]Direct non-proteolytic E3 ligase substrate/VHL-associated downstream effectors (K63-linked polyubiquitination)VHL physically engages nCLU directly at its β-domain and specifically catalyzes the K63-linked polyubiquitination of nCLU.Direct co-IP, biochemical mapping, in vitro ubiquitination assays; cell line models (nucleocytoplasmic trafficking); Human RCC tissue IHC and cell culture supernatant analysis.nCLU nucleocytoplasmic translocation signaling: The precise K63-linked ubiquitin topology serves strictly as a spatial localization signal and induces distinct cellular morphological alterations without necessarily triggering apoptosis, actively driving the nucleocytoplasmic translocation of nCLU.Potential diagnostic (Altered clusterin subcellular localization or secretory level correlates with VHL functional inactivation independently of HIF-α accumulation).Potential tissue IHC or fluid-based surrogate biomarker for assessing HIF-independent VHL functional loss in RCC. The research progress of VHL novel targets Prognostic (Fuhrman grade, PFS). Predictive (Sunitinib resistance). Candidate diagnostic (Readout of functional VHL loss); Potential predictive (CDK4/6 inhibitor sensitivity). Prognostic (Elevated p-AKT indicates aggressive disease & poor clinical outcome); Potential Predictive/Pharmacodynamic (Marker for PI3K/AKT/mTOR inhibitor sensitivity & target engagement). Fig. 2Illustration of the interaction modes between VHL and its non-canonical targets. (A) E3 ligase substrates. (B) Degradation-independent VHL-binding proteins. (C) VHL-associated downstream effectors. (D) VHL-stabilized clients. Collectively, this modular framework comprehensively decodes the multifaceted regulatory outputs governed by intact VHL. Created with BioRender.com/2p5qkh4 Illustration of the interaction modes between VHL and its non-canonical targets. (A) E3 ligase substrates. (B) Degradation-independent VHL-binding proteins. (C) VHL-associated downstream effectors. (D) VHL-stabilized clients. Collectively, this modular framework comprehensively decodes the multifaceted regulatory outputs governed by intact VHL. Created with BioRender.com/2p5qkh4 Epigenetic remodeling & chromatin dynamics ZHX2 Zinc fingers and homeoboxes 2 (ZHX2) was identified as a novel VHL substrate through an in vitro genome-wide cDNA library screening based on the notion that prolyl-hydroxylated proteins could be recognized by VHL E3 ligase [26]. This discovery established a direct mechanism parallel to HIF-α. Under normoxia, prolyl hydroxylases [PHDs, i.e., egg-laying-defective nine (EglN)] hydroxylate ZHX2, prompting VHL-mediated polyubiquitination and proteasomal degradation. Consequently, VHL loss leads to ZHX2 stabilization, as verified in ccRCC and CNS hemangioblastomas [26, 30]. ZHX2 drives oncogenesis via epigenetic reprogramming. Integrated multi-omics reveal that accumulated ZHX2 acts as an essential chromatin-anchoring co-factor. ZHX2 physically interacts with the NF-κB p65 subunit, facilitating its nuclear translocation and co-occupying ~75% of p65 genomic targets—specifically tethering to active promoter regions enriched with H3K4me3 and H3K27ac marks. In ccRCC cell lines and mouse xenograft models, this promotes NF-κB-dependent transcription, conferring resistance to apoptosis [26, 68]. In vitro studies further demonstrate that the Hippo pathway effector Yes1-associated transcriptional regulator (YAP) antagonizes this axis by competing with ZHX2 for p65 binding, thereby repressing NF-κB target genes [69]. Collectively, this sophisticated VHL-ZHX2-NF-κB-YAP crosstalk exemplifies how VHL substrates influence malignant progression and evade programmed cell death via transcriptional modulation. Beyond chromatin dynamics, cell-based experiments demonstrate that ZHX2 transcriptionally activates mitogen-activated protein kinase 1 (MEK1)/extracellular regulated protein kinases 1/2 (ERK1/2) signaling [70], upregulating downstream signal transducer and activator of transcription 3 (STAT3), and c-Jun N-terminal kinase (JNK) to drive tumor angiogenesis, growth and metastasis in ccRCC. It also induces protective autophagy, mediating sunitinib resistance in vitro [70]. Clinically, elevated ZHX2 expression functions as a prognostic biomarker associated with advanced Fuhrman grade and shorter progression-free survival (PFS) in ccRCC patient cohorts [70]. Preclinically, ZHX2 also serves as a potential predictive biomarker for sunitinib resistance, offering a prospective therapeutic target to overcome treatment failure [70]. SFMBT1 Scm-like with four malignant brain tumor domains 1 (SFMBT1) is a direct, hydroxylation-dependent VHL E3 ligase substrate emerged from the same genome-wide screening effort that identified ZHX2, underscoring the utility of systematic approaches in expanding the VHL substrate repertoire. Under normoxia, EglN1 hydroxylates SFMBT1 at Pro651, creating a recognition interface for VHL-mediated polyubiquitination and proteasomal degradation [27]. Consequently, VHL inactivation leads to SFMBT1 accumulation, as confirmed biochemically and validated in cell lines and orthotopic ccRCC mouse models. Accumulated SFMBT1 recognizes mono- and di-methylated histone lysines to modulate chromatin dynamics and transcriptional programs. Multi-omics analyses identify sphingosine kinase 1 (SPHK1) as a key downstream target that is transcriptionally upregulated to drive sphingosine-1-phosphate (S1P) signaling [27]. SPHK1 converts pro-apoptotic sphingosine into the highly bioactive lipid S1P, which signals through S1P G-protein coupled receptors (S1PRs) to promote cell proliferation and angiogenesis [71]. Clinically, elevated SFMBT1 expression—alone or in combination with high ZHX2 levels—serves as a prognostic biomarker correlated with poorer OS in ccRCC patient cohorts [72]. Preclinically, activation of the SFMBT1–SPHK1–S1P axis operates as a HIF-independent survival bypass mechanism mediating resistance to HIF-2α inhibitors and TKIs, positioning SFMBT1 as a potential predictive biomarker for treatment resistance [27, 71]. Pharmacological inhibition of downstream S1P signaling restores drug sensitivity in resistant ccRCC models, highlighting a rational therapeutic strategy to overcome resistance [71]. This axis may provide a candidate bypass vulnerability in HIF-2α-inhibitor-resistant ccRCC. SETDB1 Through analysis of the VHL physical interactome, SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) was identified as a direct, hydroxylation-dependent VHL E3 ligase substrate. Under normoxia, EglN-mediated proline hydroxylation targets SETDB1 for VHL-dependent polyubiquitination and proteasomal degradation. Hypoxia or VHL inactivation leads to SETDB1 accumulation, as demonstrated biochemically and in cell line models [25]. Accumulated SETDB1 catalyzes H3K9 trimethylation (H3K9me3) to repress transposable elements (TEs), thereby suppressing the pathological transcription of endogenous double-stranded RNA (dsRNA) and attenuating downstream type I interferon-mediated innate immune sensing [25, 31]. SETDB1 also epigenetically silences key tumor suppressors (e.g., p21) through promoter H3K9 methylation to promote tumorigenesis [32, 73]. Notably, SETDB1 displays context-dependent and double-edged functions in tumor biology. While SETDB1 stabilization promotes immune evasion and cell proliferation in VHL-deficient ccRCC and other solid tumors [31, 32], SETDB1 simultaneously acts as an essential guardian of genome stability under hypoxic stress, where its complete loss induces severe DNA damage alongside immunogenic viral mimicry [25]. Clinically, high SETDB1 expression functions as a prognostic biomarker correlated with advanced disease stage and poor OS across multiple cancers [32, 73]. Preclinically, SETDB1 elevation acts as a predictive biomarker for resistance to ICIs by dampening intrinsic tumor immunogenicity [25, 31]. Pharmacological or genetic inhibition of SETDB1 reactivates viral mimicry and restores anti-tumor immunity in mouse xenograft models, positioning SETDB1 as a potential therapeutic target to overcome immunotherapy resistance in VHL-mutant malignancies [25, 31]. VHL-linked epitranscriptomic regulation and RNA fate Beyond its chromatin-centered roles, VHL also regulates gene expression at the epitranscriptomic level. VHL serves as a non-degradative assembly scaffold for the methyltransferase-like 3 (METTL3)/METTL14 N6-methyladenosine (m6A) methyltransferase complex in a HIF-independent manner. Rather than inducing proteasomal degradation, VHL utilizes its E3 ligase domain to facilitate writer complex assembly and transcriptomic m6A deposition [33]. Integrated methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA-seq identified phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) as a key downstream effector. VHL-dependent m6A modification enables insulin-like growth factor 2 mRNA-binding protein 1/2 (IGF2BP1/2)-mediated PIK3R3 mRNA stabilization. Consequently, VHL loss accelerates PIK3R3 transcript decay, releasing PI3K/AKT signaling to promote tumorigenesis in three-dimensional culture and orthotopic mouse models [33]. Thus, reduced PIK3R3 expression may serve as a candidate predictive biomarker for PI3K/AKT pathway inhibitor sensitivity, though further validation remains required. Global m6A abundance may similarly function as a pharmacodynamic biomarker for intact VHL scaffold activity. Complementing this direct regulatory axis, the m6A demethylase fat mass and obesity-associated protein (FTO) represents a HIF-independent synthetic lethal partner rather than a direct VHL target. Genetic or pharmacological inhibition of FTO selectively impairs VHL-deficient ccRCC growth in cell lines and xenografts by restoring m6A and suppressing SLC1A5-mediated glutamine transport [34]. Here, VHL loss functions as a predictive biomarker for FTO inhibitor responsiveness. Additionally, other RNA-modifying enzymes (e.g., NOP2, NAT10, PUS1) influence ccRCC phenotypes but lack evidence of direct VHL regulation, representing broad disease-context markers rather than non-canonical VHL targets [74–76]. Transcriptional rewiring & cell cycle control RPB1 RPB1 (encoded by POLR2A), the catalytic subunit of RNA polymerase II, is a direct, hydroxylation-dependent VHL substrate. Under normoxia, PHD1 hydroxylates RPB1 at Pro1465 (LGQLAP motif), triggering VHL-mediated polyubiquitination and proteasomal clearance [35, 36]. Rather than following a single oncogenic model, RPB1 regulation reveals a context-dependent biological paradox across distinct tumor settings. In VHL-deficient ccRCC, failure to degrade RPB1 causes its accumulation, altering global transcriptional elongation kinetics [37]. Tissue accumulation of hyperphosphorylated RPB1 serves as a candidate surrogate biomarker for functional VHL loss. Paradoxically, in VHL-proficient malignancies under oxidative stress, an altered PHD1/PHD2 ratio drives Pro1465 hyper-hydroxylation and C-terminal domain Ser5 phosphorylation. Rather than inducing clearance, this modification operates alongside functional VHL to alter elongation speed, selectively upregulating cell-cycle drivers (CDC25A, CDK2, CCNA2) while repressing CDC25B to accelerate tumor growth in cell lines and xenograft models [36]. Thus, while failure of Pro1465-mediated degradation drives RPB1 accumulation in VHL-deficient ccRCC, this hydroxylation mark functions as a stress-adaptive transcriptional driver in VHL-proficient cancers under oxidative stress. This axis represents a potential predictive biomarker to guide cell-cycle or PHD1-targeted therapies based on VHL status and oxidative stress. pRB Expanding its regulatory footprint into the core cell cycle machinery, VHL governs the oxygen-sensitive ubiquitination and subsequent proteasomal clearance of the retinoblastoma protein (pRB). In VHL-deficient ccRCC, pathogenic VHL ablation triggers pRB hyperstabilization [38]. Concurrently, HIF-driven Cyclin D1 upregulation induces pRB hyperphosphorylation [77], attenuating its canonical E2F-sequestering function while simultaneously unleashing a context-dependent anti-apoptotic function [77, 78], and repressing Ski/Dach domain-containing protein 1 (SKIDA1) to support clonogenic survival in cell lines and xenografts [38]. Because VHL-deficient carcinomas become uniquely addicted to this hyperphosphorylated pRB network for survival, uncoupling this axis exposes vulnerability. Genetic pRB depletion or pharmacological upstream blockade via dual CDK4/6 inhibitors induces striking synthetic lethality across cell lines, xenografts, and cross-species models [39, 40]. Clinically, pRB accumulation and SKIDA1 repression serve as candidate diagnostic biomarkers for functional VHL loss, providing rationales for potential predictive stratification of VHL-deficient tumors for CDK4/6-targeted therapeutics. B-Myb B-Myb (Myb-related protein B) is a direct VHL E3 ligase substrate targeted for proteasomal degradation, an interaction inhibited by receptor tyrosine kinase (RTK)-mediated (VEGF/PDGF) Tyr15 phosphorylation [41, 79]. B-Myb displays a context-dependent biological paradox. While canonically acting as a pro-proliferative driver in other malignancies [79], B-Myb functions as a tumor suppressor in VHL-deficient ccRCC. Mechanistically, accumulated B-Myb selectively represses HIF-2α-dependent transcriptional programs (regulating CFB, FKBP1B, and SEPT6), where its depletion accelerates ccRCC tumor growth in cell lines and mouse xenograft models [41]. More detailed molecular mechanism remains to be elucidated. Growth factor signaling axes & signal transduction hubs EGFR Beyond indirect HIF-dependent transcriptional regulation, VHL directly functions as an E3 ligase for activated epidermal growth factor receptor (EGFR), promoting its Casitas B-lineage lymphoma proto-oncogene (c-Cbl)-independent polyubiquitination and proteasomal clearance in cell line models [80]. Loss of VHL impairs this degradation pathway, leading to EGFR accumulation in early endosomes and sustained downstream oncogenic cascades (e.g., Ras/MAPK, PI3K/AKT) [42]. In patient tissue specimens, observational evidence confirms elevated EGFR and TGFα expression in VHL-associated CNS hemangioblastomas, which correlates with tumor cystic expansion [43], supporting EGFR accumulation as a potential predictive marker for hemangioblastoma severity. EPOR Erythropoietin receptor (EPOR)-JAK2–STAT5 signaling is responsible for cell proliferation and ultimate differentiation into mature oxygen-carrying red blood cells. Beyond HIF-mediated transcriptional regulation [81], VHL directly acts as an E3 ligase for EPOR, targeting it for proteasomal degradation following PHD3-mediated hydroxylation at Pro419 and Pro426 in cell line models [44]. VHL inactivation aberrantly stabilizes the EPOR, unleashing constitutive downstream JAK2–STAT5 signaling, which is likely involved in the pathogenesis of specific VHL disease phenotypes such as pheochromocytoma and hemangioblastoma [44]. The value of EPOR as a biomarker remains unvalidated, awaiting clinical cohort and trial validation. Spry2 Sprouty proteins modulate the actions of RTK during development and tumorigenesis [82]. Previous study reported that Spry2 acts as a direct VHL E3 ligase substrate in cell line models. Under normoxia, PHD1-3-mediated hydroxylation at Pro18, Pro144, and Pro160 targets Spry2 for VHL-dependent polyubiquitination and proteasomal degradation [45]. Hypoxia or pathogenic VHL deficiency leads to Spry2 accumulation, which inhibits fibroblast growth factor (FGF)-elicited ERK1/2 activation while paradoxically protects growth factor receptors from c-Cbl-mediated degradation, thereby contributing toward the disease [45]. The value of Spry2 as a predictive biomarker for RTK signaling dysregulation requires further validation. AKT Departing from its classical E3 ligase paradigm, VHL acts as a degradation-independent scaffold regulating the PI3K/protein kinase B (AKT)/mTOR (PAM) pathway in ccRCC. Under normoxia, EglN1-mediated prolyl hydroxylation at Pro125 and Pro347 promotes AKT binding to VHL, which directly recruits the serine/threonine phosphatase protein phosphatase 2A catalytic subunit (PP2AC) to dephosphorylate and inactivate AKT without altering its protein abundance [46]. In cell line and xenograft models, VHL loss or mutation abolishes PP2AC recruitment, causing HIF-independent AKT hyperactivation—a catalyst for aggressive proliferation, metabolic rewiring, and diminished clinical survival. Elevated phospho-AKT (p-AKT) correlates with advanced stage and reduced survival in ccRCC, serving as a proposed prognostic biomarker [83]. Furthermore, p-AKT represents a potential predictive biomarker for sensitivity to PI3K/AKT/mTOR pathway inhibitors and a pharmacodynamic marker for monitoring target engagement, although validation in clinical trials remains limited [84]. Metabolic reprogramming & cellular stress sensors NDRG3 A study utilizing immunoprecipitation and mass spectrometry identified N-myc downstream regulated gene 3 (NDRG3) as a direct VHL E3 ligase substrate targeted for proteasomal degradation via PHD2-mediated hydroxylation under normoxia [29]. Under prolonged hypoxia, accumulating intracellular lactate (the ubiquitous byproduct of the Warburg effect) directly binds NDRG3, physically blocking its interaction with VHL and leading to HIF-independent NDRG3 stabilization [47]. Once stabilized, NDRG3 orchestrates a dual-pronged adaptation strategy. In cell line and xenograft models, NDRG3 physically interacts with c-Raf to activate Raf-ERK signaling, thereby driving cell proliferation and tumor angiogenesis [29, 47]. Concurrently, NDRG3 interacts with Syntaxin-5 to decelerate endoplasmic reticulum (ER)-to-Golgi vesicular transport under hypoxic and high-lactate conditions. This stress-induced attenuation of the secretory pathway mitigates ER stress, conserves critical cellular energy reserves, and prevents the lethal accumulation of misfolded proteins in the ER during metabolic starvation [85]. Furthermore, in later stage of hypoxia, upregulated lactate promotes NDRG3 accumulation, which acts as a temporal feedback regulator by suppressing AKT-driven HIF-1α translation and p300 recruitment, thereby inhibiting the metastatic potential in prostate cancer (PCa) [86]. This elegant functional transition shifts the cellular priority from acute hypoxic survival to chronic metabolic and secretory resilience. Conceptually, NDRG3 accumulation serves as a proposed prognostic biomarker for hypoxic metabolic stress adaptation and a hypothetical predictive biomarker for targeting the lactate-NDRG3 axis to overcome therapy-resistant, chronically hypoxic malignancies, though prospective clinical validation remains required. TFAM Beyond substrate degradation, VHL regulates mitochondrial biogenesis by physically stabilizing mitochondrial transcription factor A (TFAM), a key activator of mitochondrial DNA replication and transcription. Following EglN3-mediated prolyl hydroxylation (Pro53/66), VHL physically binds TFAM, competitively shielding it from cleavage by the mitochondrial protease LONP1 [48]. In cell line and xenograft models, oncogenic VHL inactivation unleashes unrestrained LONP1 activity, precipitating mitochondrial depletion. This targeted eradication of oxidative phosphorylation capacity metabolically locks ccRCC cells into the Warburg effect, while simultaneously exacerbating ROS accumulation and inflammatory signaling (e.g., p-JNK, LCN2). Clinically, low TFAM expression and mitochondrial depletion correlate with VHL-deficient malignancies including ccRCC and pheochromocytoma, serving as a proposed diagnostic biomarker. Furthermore, high LONP1 activity represents a potential predictive biomarker for sensitivity blockade via bortezomib (a non-selective proteasome inhibitor with LONP1-inhibiting activity), which restores mitochondrial biogenesis and resensitizes VHL-deficient ccRCC to sorafenib in preclinical models [48]. Further clinical validation remains required. Extracellular matrix & cytoskeletal architecture Fibronectin Fibronectin is a high-molecular-weight glycoprotein found in the extracellular matrix (ECM) and bodily fluids, playing key roles in various biological processes such as cell adhesion, migration, tissue repair, and embryonic development [87]. Fibronectin represents a direct non-degradative binding partner and ECM assembly client of VHL. VHL (wild-type but not various missense mutants under stringent conditions) physically interacts with fibronectin in vivo under physiological conditions to facilitate assembly of the insoluble pericellular fibronectin matrix, while also regulating fibronectin transcription independently of HIF [49, 88]. Pathogenic VHL mutations abolish fibronectin binding and matrix assembly, promoting cell proliferation, migration and invasive phenotypes in cell line and xenograft models. Clinically, disrupted fibronectin matrix architecture strongly correlates with VHL-deficient ccRCC tissues and serves as a proposed diagnostic biomarker for VHL inactivation and invasive ECM remodeling [49, 50, 88]. COL4A2 Beyond interacting with fibronectin, VHL regulates ECM architecture through collagen IV. Independently of HIF regulation, VHL acts as a direct non-degradative binding partner and matrix assembly client for collagen IV alpha 2 (COL4A2). Following ER-mediated prolyl hydroxylation of COL4A2, VHL physically binds its unfolded N-terminal chain to facilitate supramolecular collagen IV network assembly [51, 52, 89]. Tumorigenic VHL mutations—including HIF-competent type 2C variants—impair COL4A2 binding and dismantle the ECM, generating a compromised, mechanically permissive TME that actively licenses unbridled vascular infiltration, pathogenic angiogenesis, and aggressive ccRCC invasion in cell line and xenograft models [52, 89]. Clinically, disrupted collagen IV matrix architecture correlates with VHL-deficient ccRCC tissue specimens, making it a proposed diagnostic biomarker for VHL inactivation (specifically type 2C phenotypes) and invasive TME remodeling, pending prospective validation. AURKA Previous studies reported that VHL safeguards the primary cilium by restricting Aurora Kinase A (AURKA) via dual convergent mechanisms: directly as an E3 ligase executing non-canonical, PHD-independent ubiquitination and degradation [53], indirectly by suppressing HIF-driven transcriptional activation of AURKA and its co-activator neural precursor cell-expressed developmentally down-regulated 9 (NEDD9)/human enhancer of filamentation 1 (HEF1) [54]. Reciprocally, AURKA phosphorylates VHL [55]. In cell line and xenograft models, VHL loss causes AURKA hyperactivation and HDAC6-mediated tubulin depolymerization, driving primary cilia disassembly, renal cystogenesis, and cell motility. In clinical tissue specimens, elevated AURKA correlates with primary cilia loss and advanced Fuhrman grade [53, 54], serving as potential diagnostic and predictive biomarkers for VHL inactivation and aggressive ccRCC. aPKC VHL intrinsically governs epithelial morphogenesis by coupling microtubule stability with atypical protein kinase C (aPKC, including PKCζ/ι) signaling. Directly interacting via its β-domain, VHL functions as a non-degradative E3 ligase client and spatial scaffold for aPKC [56, 90]. VHL selectively ubiquitinates active, phosphorylated aPKC to regulate its membrane anchoring and maintain cell polarity, co-facilitating the endo-lysosomal internalization and the degradation of pro-metastatic α5 integrin. In cell line models, VHL loss uncouples aPKC spatial regulation, resulting in tight junction disassembly, surface α5 integrin accumulation, and increased cell invasion [57, 90, 91]. Consequently, aberrant aPKC localization/activation and α5 integrin stabilization serve as proposed diagnostic and predictive biomarkers for VHL inactivation and invasive ccRCC phenotypes. Immune modulation & inflammatory signaling TBK1 TANK-binding kinase 1 (TBK1) functions as a degradation-independent VHL-binding partner rather than a classical ubiquitin substrate. Under normoxia, EglN1-hydroxylated TBK1 (at Pro48) binds to VHL, which recruits protein phosphatase, Mg2 +/Mn2 + dependent 1B (PPM1B). PPM1B dephosphorylates and inactivates TBK1. Conversely, VHL-deficiency or hypoxia impairs PPM1B recruitment, resulting in persistent TBK1 phosphorylated and hyperactive [28]. The downstream effects of TBK1 exhibit distinct context-dependent cell functions. Canonically, stimulator of interferon genes (STING)-activated TBK1 in immune cells drives type I interferon (IFN) expression and anti-tumor immunity. In VHL-deficient ccRCC cells, VHL loss and secondary HIF accumulation contribute to immunosuppressive TME remodeling by stimulating pro-inflammatory factors (e.g., CX3CL1, CCL2), recruiting tumor-associated macrophages and myeloid-derived suppressor cells, and impairing T-cell function—key drivers of resistance to ICIs. Within this framework, TBK1 is rewired away from IFN signaling. Hyperactivated TBK1 phosphorylates p62 at Ser366, which facilitates the degradation of specific proteins by modulating pro-tumorigenic autophagy signaling, and promotes cell proliferation and xenograft ccRCC growth. Elevated phospho-TBK1 and VHL loss serve as proposed predictive biomarkers for synthetic lethal sensitivity to TBK1 inhibitors [28, 92]. Therefore, aberrant TBK1 activation not only supports pro-survival autophagic flux and metabolic adaptation, but also offers dual therapeutic potential by exploiting synthetic lethality in VHL-deficient ccRCC and potentially modulating myeloid-driven immune evasion to restore ICIs sensitivity. RIPK1 Receptor-interacting protein kinase 1 (RIPK1) is regulated by VHL via a non-canonical, degradation-independent mechanism. Under normoxia, EglN1 hydroxylates RIPK1 on prolyl residues, directly suppressing RIPK1 kinase activity (autophosphorylation at Ser166) and preserving cell survival. Conversely, prolonged hypoxia or VHL loss reduces RIPK1 prolyl hydroxylation and alleviates this inhibition, unleashing RIPK1 kinase-dependent necroptosis and pro-inflammatory signaling [59]. RIPK1 signaling displays functional context-dependency, oscillating between kinase-mediated cell death and scaffold-mediated survival/immunosuppression. Beyond its kinase activity, RIPK1 functions as a molecular scaffold that subverts tumor necrosis factor (TNF) signaling away from CASP8-dependent apoptosis and toward NF-κB-driven survival. Extrinsically, this scaffold activity drives an immunosuppressive cytokine network that remodels the TME—promoting ARG1+ suppressive myeloid cell accumulation and excluding cytotoxic T and natural killer (NK) cells—thereby mediating resistance to ICIs [93]. Furthermore, another study demonstrated that the O-linked β-N-acetyglucosamine modification (O-GlcNAcylation) of RIPK1 induced sunitnib resistance in RCC by inhibiting RIPK-dependent apoptosis [94]. Supported by biochemical binding assays, RCC cell lines, and mouse tumor models, phospho-RIPK1 (Ser166) and RIPK1 modification status serve as proposed predictive biomarkers for ICI resistance, TKI non-responsiveness, and sensitivity to RIPK1-targeted inhibitors. Further clinical investigations are warranted. Hierarchical ubiquitin ligase cascades UBE3B Expanding its regulatory architecture into inter-ligase crosstalk, VHL regulates hierarchical E3 ubiquitin ligase cascades by directly targeting the subordinate ligase ubiquitin protein ligase E3B (UBE3B) for proteasomal degradation. Operating independently of oxygen tension and EglN1-mediated hydroxylation, the VHL β-domain physically engages UBE3B, driving its K48-linked polyubiquitination specifically at residues K286 and K427 to enforce rapid proteasomal clearance [60]. Reciprocally, UBE3B acts as an oxygen-independent stabilizer of HIF-2α, shielding it from VHL-mediated degradation even when canonical prolyl residues (Pro405/531) are mutated [95]. Recent evidence suggests that UBE3B plays a crucial role in cancer progression and drug resistance [96, 97]. By actively destroying UBE3B, VHL dismantles this oncogenic bypass, thereby imposing a critical secondary failsafe against HIF-2α hyperactivation. Conversely, VHL deficiency leads to UBE3B accumulation, which promotes tumor cell proliferation and pulmonary metastasis, as demonstrated in breast cancer cell lines and mouse xenograft models. Clinically, high protein levels of UBE3B positively correlated with poor OS of breast cancer patients, highlighting elevated UBE3B as a prognostic biomarker for aggressive disease and metastatic risk, as well as a candidate therapeutic target [60, 95]. JADE1 VHL functions as a critical stabilizing chaperone for Jade family plant homeodomain finger 1 (JADE1), a renal-preferential tumor suppressor and E3 ubiquitin ligase [98]. Mechanistically, VHL engages JADE1 via its β-domain and maintains JADE1 protein stability through its α-domain [61]. Notably, truncations or ccRCC-associated VHL missense mutations (e.g., L118P, R167W)—unlike non-ccRCC variants (e.g., Y98H)—selectively abolish JADE1 stabilization, directly linking the loss of JADE1 stability to ccRCC risk [61–63]. Downstream, stabilized JADE1 ubiquitinates both phosphorylated and non-phosphorylated β-catenin to suppress Wnt signaling, while physically binding and repressing endogenous levels of active phospho-AKT1 [61, 64]. Therefore, VHL deficiency leads to JADE1 protein depletion, driving a dual oncogenic surge (concurrent β-catenin and AKT pathway hyperactivation) in ccRCC cell lines and structural models. Database analysis suggested that reduced Jade-1 expression is associated with advanced tumor stage, high pathological grade and more patient deaths [64], making it a poor prognostic factor for ccRCC. Non-proteolytic topologies & steric shielding BIM-EL Similar to JADE1, VHL acts as a critical stabilizing chaperone for the pro-apoptotic BH3-only protein BIM-EL. Following EglN3-mediated prolyl hydroxylation at Pro67 and Pro70, VHL physically binds BIM-EL, sterically blocking adjacent Ser69 residue from ERK-dependent phosphorylation and subsequent proteasomal degradation [65, 66]. Type 2C VHL missense mutations selectively disrupt this interaction while retaining HIF-α degradative capacity, preventing sympathoadrenal lineage cell apoptosis and contributing to familial pheochromocytoma/paraganglioma pathogenesis [99]. In RCC cell lines, VHL loss depletes BIM-EL pools and confers resistance to DNA-damaging chemotherapeutics (e.g., cisplatin), an effect reversed by pharmacological ERK inhibition [100]. Therefore, BIM-EL protein status represents a proposed predictive biomarker for chemotherapeutic non-responsiveness and MEK/ERK inhibitor combination sensitivity in VHL-deficient tumors, as well as a potential diagnostic marker for type 2C VHL-associated pheochromocytoma. nCLU VHL functions as a non-proteolytic E3 ubiquitin ligase for nuclear clusterin (nCLU). Mechanistically, VHL engages nCLU via its β-domain to catalyze K63-linked—rather than canonical K48-linked—polyubiquitination, directing nCLU nucleocytoplasmic translocation and cellular morphological changes without inducing proteasomal degradation. Demonstrated primarily in RCC cell lines and human tissue specimens, clusterin expression, secretion, and subcellular localization correlate with VHL functional status independently of HIF-α [67, 101]. Ultimately, this paradigm establishes VHL not merely as a destructive ligase, but as a versatile post-translational spatial coordinator that dynamically fine-tunes intracellular trafficking and signaling networks. However, the physiological function of VHL mediating nCLU ubiquitination and its prospective clinical utility are still unclear and require further investigation. VHL dysregulation in pan-cancer contexts Driven by the rapid evolution of multi-omics and high-throughput profiling, contemporary oncology recognizes VHL as a pleiotropic tumor suppressor occurring across several non-renal malignancies. However, VHL functions are highly tissue-dependent, and non-renal tumor phenotypes vary substantially based on cellular lineage. Consequently, canonical VHL mechanisms established in ccRCC cannot be universally extrapolated to other cancer contexts without direct experimental validation. To critically assess non-renal VHL dysregulation, we classify reported alterations into four evidence tiers: (1) genetic/truncal disruptions with demonstrated causality; (2) epigenetic or post-translational suppression of wild-type VHL; (3) context-dependent VHL-associated rewiring; and (4) correlative transcriptomic associations lacking functional validation (Table 2). This section synthesizes the pan-cancer genomic landscape, tissue-specific molecular mechanisms, and transformative clinical implications of VHL dysregulation beyond RCC (Fig. 3).Table 2The research progress of VHL in non-RCC tumorigenesisMalignanciesStatus of VHLLevel of EvidenceRole of VHL in TumorigenesisPotential Clinical ApplicationLung cancer [102–109]Rare somatic mutations (<5%). Hypermethylation of the VHL promoter. Inactivation of VHL via allelic loss. LOH at the VHL locus.In vitro NSCLC cell line knockdowns (paradoxically reduces growth/colonization). In vivo mouse genetic models (FHIT±VHL± mouse lung adenocarcinoma). Retrospective human tissue allelotyping & methylation cohorts.Concurrent ablation of VHL and FHIT, including haploinsufficiency of VHL predisposes to spontaneous and induced lung cancers in murine models. Knockdown of VHL decreased phosphorylation of FAK and expression of integrin, and promoted EMT in lung cancer cells.Molecular stratification of 3p-deleted NSCLC. Evaluation of epigenetic multi-hit tumor suppressor loss in lung oncogenesis.Malignant mesothelioma [110–112]Inactivating VHL mutations and genomic near-haploidization.In vitro VHL-mutant MPM cell line apoptosis assays upon HIF-1α knockdown. Small clinical genomic case series/cohorts.Clear cell MPM cells are addicted to the uninhibited HIF cascade generated by VHL loss. Targeted HIF-1α depletion rapidly induces PARP-mediated apoptosis in MPM cells.Differential diagnosis of thoracic clear cell neoplasms. Candidate selection for HIF-α inhibitor trials (e.g., belzutifan), subject to prospective clinical validation.Breast cancer [60, 95, 113, 114]Somatic VHL mutation is rare. Tumor-suppressive VHL axis is mainly dismantled via epigenetic hypermethylation and aberrant post-translational degradation.In vitro biochemistry (CDK1/PIN1/WSB1 binding, Ser80 phosphorylation, UBE3B ubiquitination). In vivo mouse xenograft models (chemoradiosensitivity restoration via ATRA/RO-3306, UBE3B-HIF-2α metastasis). Retrospective clinical tissue IHC cohorts.Wild-type VHL is actively eradicated via the pathogenic CDK1–PIN1–WSB1 cascade, conferring chemotherapeutic resistance. VHL-mediated UBE3B degradation suppresses breast tumor growth and metastasis. VHL expression inversely correlates with tumor grade, axillary node metastasis, clinical prognosis and local recurrence.Patient risk stratification based on VHL expression. Rationale for PIN1/CDK1 inhibitor combination therapy to restabilize VHL, though pharmacokinetics and clinical toxicity require further investigation.Thyroid carcinoma [115–119]Negative correlation between VHL and oncogenic miRNAs, specifically miR-21 and miR-92a, was observed.In vitro biochemistry & cell line assays (3’-UTR miR-21 direct targeting, VHL/PI3K/AKT EMT regulation). Retrospective clinical mRNA/IHC cohort studies.In some PTC cases, VHL functions as a highly dynamic transcriptomic biomarker whose progressive downregulation strongly correlates with aggressive clinicopathological features, including extrathyroidal extension, lymph node metastasis, and diminished disease-free survival. This non-genomic silencing may be orchestrated by aberrant microRNA networks.Preclinical rationale for targeting oncogenic miRNAs (e.g., antagomirs) to restore VHL expression; currently lacks in vivo efficacy, pharmacokinetic, and clinical safety data.Pancreatic endocrine tumors [120]Nearly 25% of all sporadic pNETs exhibit functionally VHL impairment (monoallelic deletion of the 3p25 locus harboring the VHL gene and promoter hypermethylation).Established germline genetic causality in syndromic pNETs. Retrospective clinical tissue cohort studies for 3p25 LOH, promoter hypermethylation, and CA-9/GLUT-1 expression in sporadic pNETs.The non-mutational VHL ablation are associated with a decreased transcription and an activation of the HIF-pathway, leading to an overexpression of HIF-1α and HIF-targets CA-9 and GLUT-1. Patients presenting with VHL-impaired sporadic pNETs experience significantly shortened DFS.Genetic screening and risk stratification in hereditary/sporadic pNETs. Preclinical rationale for targeting downstream metabolic effectors (CA-9, GLUT-1); limited by tumor heterogeneity, drug delivery barriers, and lack of validated targeted agents.PPGLs [121]VHL inactivation (often alongside SDHx and PHD mutations).Established causal genetic driver in cluster 1 hereditary PPGLs. In vitro and preclinical metabolic studies on pseudohypoxic glycolysis (Warburg effect) and non-coding RNA networks.Mutations in the VHL/HIF axis drive tumorigenesis through mechanisms of pseudohypoxia and metabolic reprogramming. Some HIF-responsive non-coding RNAs (e.g., miR-210, and lncRNA MALAT1) are involved in metabolic subversion and orchestrate aggressive metastasis and neuroendocrine dedifferentiation.Molecular subtyping to guide patient management and surveillance. Preclinical rationale for HIF-2α inhibitors (e.g., belzutifan) or metabolic targeted therapies; limitations include systemic toxicities, off-target effects, and need for prospective clinical validation.CNS Hemangioblastoma [122]Germline VHL gene mutation/LOH leading to constitutive HIF-1/2α stabilization and downstream JAK2/STAT3 signaling activation.Established causal genetic driver in VHL disease. Patient-derived primary cell cultures & mechanistic studies.VHL dysregulation stabilizes HIF-1/2α and completely removes the regulatory brakes on the JAK2/STAT3 signaling cascade, promoting aggressive hemangioblast progenitor cell expansion deeply within the CNS microenvironment.Diagnostic stratification for VHL disease. Dual HIF-1/2α or belzutifan-based targeting; long-term clinical efficacy in non-ccRCC CNS lesions requires continued trial monitoring.Glioblastoma [123–125]Post-translational degradation (FBXO22, Daam2) and post-transcriptional silencing by microRNAs (miR-150, miR-23b, miR-566); somatic VHL mutations are rare.In vitro reporter/ubiquitination assays & orthotopic/subcutaneous mouse xenografts. Retrospective clinical expression correlations.In glioblastoma, wild-type VHL is systematically eradicated via a highly coordinated post-translational and epigenetic web. VHL downregulation promotes cell survival, stemness, and invasion.Rationale for targeting upstream E3 ligases (FBXO22) or oncogenic miRNAs. Therapeutic translation is severely constrained by blood-brain barrier penetration, profound glioblastoma intratumoral heterogeneity, and complete lack of clinical validation.Multiple myeloma [126]Epigenetic silencing via targeted VHL promoter hypermethylation (e.g., methylation in the VHL CpG island); somatic VHL mutations are absent.Retrospective patient cohort correlation study.The epigenetic ablation of VHL decreases HIF-1α proteolysis. It fundamentally alters the local bone marrow microenvironment, driving explosive local angiogenesis and accelerating the metabolic shift toward continuous aerobic glycolysis. This highly vascularized and acidic marrow niche provides a deeply protective sanctuary for malignant plasma cells, promoting their survival, immune evasion, and the rapid progression of destructive, painful osteolytic bone disease.Potential biomarker for predicting destructive skeletal progression.DLBCL [127]Epigenetic VHL promoter hypermethylation; post-transcriptional suppression mediated by oncogenic microRNA (miR-21).Retrospective clinical cohort association for promoter hypermethylation. Single cell-line in vitro functional assays for miR-21 regulation.Dismantling VHL strongly predicts high IPI scores and dismal survival. Curcumin inhibits miR-21 expression and restabilizes VHL, severely restricting DLBCL proliferation and inducing apoptosis.Potential prognostic risk stratification for aggressive disease. Preclinical rationale for miR-21 antagonism; limited by strictly in vitro evidence, delivery barriers, and tumor heterogeneity.HNSCC [128, 129]Chromosome 3p LOH at VHL locus (biallelic sequence mutations absent); post-transcriptional suppression by oncogenic miR-21 driving STAT3/β-catenin signaling.LOH and immunohistochemical correlation in patient tissue cohorts. Cell-line and orthotopic xenograft assays for STAT3/miR-21/VHL axis.VHL cytoplasmic expression spatially expands during premalignant dysplasia and invasive carcinogenesis, tightly co-localizing with the basal proliferative marker CK17. VHL pool is aggressively neutralized at the post-transcriptional level by oncogenic miR-21, which dismantles its tumor-suppressive capacity, unleashing downstream STAT3 and β-catenin cascades to drive robust invasion.Potential adjunctive marker for early dysplastic transformation. Preclinical rationale for STAT3/miR-21 inhibition (e.g., HJC0152); limited by lack of clinical phase studies, potential target-related toxicities of systemic STAT3 inhibition, and tumor heterogeneity.Fig. 3The pan-cancer landscape of VHL dysregulation beyond RCC. The schematic delineates the diverse genetic, epigenetic, and post-translational mechanisms driving VHL inactivation across non-renal malignancies. Arrow color and line styles denote the level of supporting evidence: blue solid arrows represent associations or pathways observed in human cohorts or observational datasets; black solid arrows indicate pathways validated by in vitro cell line, molecular, or biochemical experiments; purple solid arrows represent pathways validated by in vivo animal models or clinical trials; dashed arrows denote hypothesized pathways lacking direct experimental validation. Created with BioRender.com/wuul6rp Table 2The research progress of VHL in non-RCC tumorigenesisMalignanciesStatus of VHLLevel of EvidenceRole of VHL in TumorigenesisPotential Clinical ApplicationLung cancer [102–109]Rare somatic mutations (<5%). Hypermethylation of the VHL promoter. Inactivation of VHL via allelic loss. LOH at the VHL locus.In vitro NSCLC cell line knockdowns (paradoxically reduces growth/colonization). In vivo mouse genetic models (FHIT±VHL± mouse lung adenocarcinoma). Retrospective human tissue allelotyping & methylation cohorts.Concurrent ablation of VHL and FHIT, including haploinsufficiency of VHL predisposes to spontaneous and induced lung cancers in murine models. Knockdown of VHL decreased phosphorylation of FAK and expression of integrin, and promoted EMT in lung cancer cells.Molecular stratification of 3p-deleted NSCLC. Evaluation of epigenetic multi-hit tumor suppressor loss in lung oncogenesis.Malignant mesothelioma [110–112]Inactivating VHL mutations and genomic near-haploidization.In vitro VHL-mutant MPM cell line apoptosis assays upon HIF-1α knockdown. Small clinical genomic case series/cohorts.Clear cell MPM cells are addicted to the uninhibited HIF cascade generated by VHL loss. Targeted HIF-1α depletion rapidly induces PARP-mediated apoptosis in MPM cells.Differential diagnosis of thoracic clear cell neoplasms. Candidate selection for HIF-α inhibitor trials (e.g., belzutifan), subject to prospective clinical validation.Breast cancer [60, 95, 113, 114]Somatic VHL mutation is rare. Tumor-suppressive VHL axis is mainly dismantled via epigenetic hypermethylation and aberrant post-translational degradation.In vitro biochemistry (CDK1/PIN1/WSB1 binding, Ser80 phosphorylation, UBE3B ubiquitination). In vivo mouse xenograft models (chemoradiosensitivity restoration via ATRA/RO-3306, UBE3B-HIF-2α metastasis). Retrospective clinical tissue IHC cohorts.Wild-type VHL is actively eradicated via the pathogenic CDK1–PIN1–WSB1 cascade, conferring chemotherapeutic resistance. VHL-mediated UBE3B degradation suppresses breast tumor growth and metastasis. VHL expression inversely correlates with tumor grade, axillary node metastasis, clinical prognosis and local recurrence.Patient risk stratification based on VHL expression. Rationale for PIN1/CDK1 inhibitor combination therapy to restabilize VHL, though pharmacokinetics and clinical toxicity require further investigation.Thyroid carcinoma [115–119]Negative correlation between VHL and oncogenic miRNAs, specifically miR-21 and miR-92a, was observed.In vitro biochemistry & cell line assays (3’-UTR miR-21 direct targeting, VHL/PI3K/AKT EMT regulation). Retrospective clinical mRNA/IHC cohort studies.In some PTC cases, VHL functions as a highly dynamic transcriptomic biomarker whose progressive downregulation strongly correlates with aggressive clinicopathological features, including extrathyroidal extension, lymph node metastasis, and diminished disease-free survival. This non-genomic silencing may be orchestrated by aberrant microRNA networks.Preclinical rationale for targeting oncogenic miRNAs (e.g., antagomirs) to restore VHL expression; currently lacks in vivo efficacy, pharmacokinetic, and clinical safety data.Pancreatic endocrine tumors [120]Nearly 25% of all sporadic pNETs exhibit functionally VHL impairment (monoallelic deletion of the 3p25 locus harboring the VHL gene and promoter hypermethylation).Established germline genetic causality in syndromic pNETs. Retrospective clinical tissue cohort studies for 3p25 LOH, promoter hypermethylation, and CA-9/GLUT-1 expression in sporadic pNETs.The non-mutational VHL ablation are associated with a decreased transcription and an activation of the HIF-pathway, leading to an overexpression of HIF-1α and HIF-targets CA-9 and GLUT-1. Patients presenting with VHL-impaired sporadic pNETs experience significantly shortened DFS.Genetic screening and risk stratification in hereditary/sporadic pNETs. Preclinical rationale for targeting downstream metabolic effectors (CA-9, GLUT-1); limited by tumor heterogeneity, drug delivery barriers, and lack of validated targeted agents.PPGLs [121]VHL inactivation (often alongside SDHx and PHD mutations).Established causal genetic driver in cluster 1 hereditary PPGLs. In vitro and preclinical metabolic studies on pseudohypoxic glycolysis (Warburg effect) and non-coding RNA networks.Mutations in the VHL/HIF axis drive tumorigenesis through mechanisms of pseudohypoxia and metabolic reprogramming. Some HIF-responsive non-coding RNAs (e.g., miR-210, and lncRNA MALAT1) are involved in metabolic subversion and orchestrate aggressive metastasis and neuroendocrine dedifferentiation.Molecular subtyping to guide patient management and surveillance. Preclinical rationale for HIF-2α inhibitors (e.g., belzutifan) or metabolic targeted therapies; limitations include systemic toxicities, off-target effects, and need for prospective clinical validation.CNS Hemangioblastoma [122]Germline VHL gene mutation/LOH leading to constitutive HIF-1/2α stabilization and downstream JAK2/STAT3 signaling activation.Established causal genetic driver in VHL disease. Patient-derived primary cell cultures & mechanistic studies.VHL dysregulation stabilizes HIF-1/2α and completely removes the regulatory brakes on the JAK2/STAT3 signaling cascade, promoting aggressive hemangioblast progenitor cell expansion deeply within the CNS microenvironment.Diagnostic stratification for VHL disease. Dual HIF-1/2α or belzutifan-based targeting; long-term clinical efficacy in non-ccRCC CNS lesions requires continued trial monitoring.Glioblastoma [123–125]Post-translational degradation (FBXO22, Daam2) and post-transcriptional silencing by microRNAs (miR-150, miR-23b, miR-566); somatic VHL mutations are rare.In vitro reporter/ubiquitination assays & orthotopic/subcutaneous mouse xenografts. Retrospective clinical expression correlations.In glioblastoma, wild-type VHL is systematically eradicated via a highly coordinated post-translational and epigenetic web. VHL downregulation promotes cell survival, stemness, and invasion.Rationale for targeting upstream E3 ligases (FBXO22) or oncogenic miRNAs. Therapeutic translation is severely constrained by blood-brain barrier penetration, profound glioblastoma intratumoral heterogeneity, and complete lack of clinical validation.Multiple myeloma [126]Epigenetic silencing via targeted VHL promoter hypermethylation (e.g., methylation in the VHL CpG island); somatic VHL mutations are absent.Retrospective patient cohort correlation study.The epigenetic ablation of VHL decreases HIF-1α proteolysis. It fundamentally alters the local bone marrow microenvironment, driving explosive local angiogenesis and accelerating the metabolic shift toward continuous aerobic glycolysis. This highly vascularized and acidic marrow niche provides a deeply protective sanctuary for malignant plasma cells, promoting their survival, immune evasion, and the rapid progression of destructive, painful osteolytic bone disease.Potential biomarker for predicting destructive skeletal progression.DLBCL [127]Epigenetic VHL promoter hypermethylation; post-transcriptional suppression mediated by oncogenic microRNA (miR-21).Retrospective clinical cohort association for promoter hypermethylation. Single cell-line in vitro functional assays for miR-21 regulation.Dismantling VHL strongly predicts high IPI scores and dismal survival. Curcumin inhibits miR-21 expression and restabilizes VHL, severely restricting DLBCL proliferation and inducing apoptosis.Potential prognostic risk stratification for aggressive disease. Preclinical rationale for miR-21 antagonism; limited by strictly in vitro evidence, delivery barriers, and tumor heterogeneity.HNSCC [128, 129]Chromosome 3p LOH at VHL locus (biallelic sequence mutations absent); post-transcriptional suppression by oncogenic miR-21 driving STAT3/β-catenin signaling.LOH and immunohistochemical correlation in patient tissue cohorts. Cell-line and orthotopic xenograft assays for STAT3/miR-21/VHL axis.VHL cytoplasmic expression spatially expands during premalignant dysplasia and invasive carcinogenesis, tightly co-localizing with the basal proliferative marker CK17. VHL pool is aggressively neutralized at the post-transcriptional level by oncogenic miR-21, which dismantles its tumor-suppressive capacity, unleashing downstream STAT3 and β-catenin cascades to drive robust invasion.Potential adjunctive marker for early dysplastic transformation. Preclinical rationale for STAT3/miR-21 inhibition (e.g., HJC0152); limited by lack of clinical phase studies, potential target-related toxicities of systemic STAT3 inhibition, and tumor heterogeneity. The research progress of VHL in non-RCC tumorigenesis The pan-cancer landscape of VHL dysregulation beyond RCC. The schematic delineates the diverse genetic, epigenetic, and post-translational mechanisms driving VHL inactivation across non-renal malignancies. Arrow color and line styles denote the level of supporting evidence: blue solid arrows represent associations or pathways observed in human cohorts or observational datasets; black solid arrows indicate pathways validated by in vitro cell line, molecular, or biochemical experiments; purple solid arrows represent pathways validated by in vivo animal models or clinical trials; dashed arrows denote hypothesized pathways lacking direct experimental validation. Created with BioRender.com/wuul6rp Thoracic malignancies: lung cancer and mesothelioma Despite rare somatic mutations (<5%), VHL down-regulation in non-small cell lung cancer (NSCLC) occurs primarily through chromosome 3p25 loss of heterozygosity (LOH) and promoter hypermethylation [102–104]. Epigenetic VHL silencing frequently co-occurs with EGFR mutations, and VHL haploinsufficiency cooperates with FHIT loss to drive lung adenocarcinoma in mice, recapitulating the classic multi-hit 3p-deletion paradigm [102, 103, 105–107]. Notably, VHL exhibits tissue-specific functional divergence: unlike its canonical tumor-suppressive role in ccRCC, VHL exerts strict, HIF-independent control over the epithelial-mesenchymal transition (EMT). VHL knockdown in NSCLC cell lines attenuates integrin/FAK signaling, paradoxically reducing cell proliferation and colonization in vitro despite inducing EMT features (E-cadherin loss, elevated α-SMA) [108, 109]. This highlights a highly context-dependent, structural mandate for VHL in the pulmonary microenvironment. In malignant pleural mesothelioma (MPM), VHL inactivating mutations occurs in an ultra-rare, distinct clear cell subtype [110–112]. Unlike canonical MPMs driven by BAP1 or NF2 loss, clear cell MPMs feature VHL mutations alongside genomic near-haploidization [130]. In vitro evidence shows that VHL-mutant MPM cell lines depend on HIF-1α for survival, where HIF-1α suppression induces poly (ADP-ribose) polymerase (PARP)-mediated apoptosis [110]. Consequently, VHL mutation status represents a potential diagnostic biomarker to distinguish clear cell MPM from classical subtypes and a speculative predictive biomarker for HIF-targeted therapies (e.g., belzutifan) [112]. More prospective clinical evaluation is required. Breast cancer In breast cancer, particularly triple-negative breast cancer (TNBC), somatic VHL mutations are exceedingly rare. Instead, VHL depletion occurs primarily via post-translational degradation and epigenetic hypermethylation. Mechanistically, cyclin-dependent kinase 1 (CDK1) phosphorylates VHL at Ser80, recruiting peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) to promote WSB1-mediated VHL ubiquitination and proteasomal degradation [113]. This targeted eradication confers chemotherapeutic resistance. Pharmacological stabilization of VHL via CDK1 or PIN1 inhibitors (e.g., RO-3306 or ATRA) successfully resensitizes TNBC cell lines to chemotherapy [113]. Furthermore, intact VHL restricts breast cancer progression by targeting the E3 ligase UBE3B for degradation. Conversely, VHL depletion stabilizes UBE3B to upregulate HIF-2α, driving tumor growth and metastasis in preclinical models [60, 95]. Clinically, reduced VHL protein expression correlates with higher tumor grade, lymph node metastasis, and shorter OS, establishing low VHL status as a proposed prognostic biomarker in breast cancer [114, 131]. Thyroid carcinoma In papillary thyroid carcinoma (PTC), VHL dysregulation diverges from canonical somatic mutations or promoter hypermethylation. Instead, it occurs predominantly through non-mutational transcriptional and post-transcriptional alterations such as alternative mRNA splicing and microRNA targeting [115, 116]. Clinical observational studies report an inverse correlation between VHL downregulation and aggressive pathological features, including lymph node metastasis and reduced disease-free survival (DFS) [116, 117]. Post-transcriptional silencing by oncogenic microRNAs (e.g., miR-21 and miR-92a) has been implicated in this process [118, 119]. Specifically, in vitro cell-line experiments indicate that miR-21 directly targets VHL to activate PI3K/AKT signaling, thereby promoting and tumor invasion [118]. However, current evidence for VHL in PTC remains largely observational or restricted to cell culture models. Independent in vivo validation and biomarker-driven therapy remain to be further elucidated. pNets and PPGLs In neuroendocrine neoplasms, VHL inactivation occurs via distinct genetic and epigenetic mechanisms depending on tumor etiology. While germline VHL mutations represent established genetic drivers of syndromic pancreatic neuroendocrine tumors (pNETs) and pheochromocytomas/paragangliomas (PPGLs), somatic VHL mutations are rare in sporadic cases. Instead, VHL inactivation occurs in approximately 25% of sporadic pNETs through 3p25 LOH and promoter hypermethylation, leading to pseudohypoxic HIF-1α accumulation and upregulated downstream metabolic effectors [e.g., carbonic anhydrase 9 (CA-9) and the glucose transporter 1 (GLUT-1)] that correlate with shortened DFS [120, 132]. In PPGLs, VHL inactivation (often clustering with SDHx and PHD mutations) contributes to pseudohypoxic metabolic reprogramming toward aerobic glycolysis and mitochondrial suppression [133]. This metabolic subversion is regulated in part by HIF-responsive non-coding RNAs (e.g., miR-210 and lncRNA MALAT1) that orchestrate aggressive metastasis and neuroendocrine dedifferentiation [121, 134]. Clinically, low VHL status and secondary pseudohypoxic markers serve as proposed negative prognostic biomarkers in sporadic pNETs [120]. However, therapeutic strategies targeting the VHL/HIF metabolic axis in neuroendocrine tumors remain largely preclinical, requiring further clinical exploration. CNS tumor In central nervous system (CNS) tumors, VHL dysregulation operates through distinct etiology-specific mechanisms. Germline VHL inactivation drives progenitor cell expansion and syndromic CNS hemangioblastomas (the pathognomonic hallmark of VHL disease) via constitutive HIF-1/2α stabilization and cross-talk with JAK2/STAT3 signaling [122, 135]. Conversely, somatic VHL mutations are rare in glioblastoma; instead, wild-type VHL is systematically eradicated via a highly coordinated post-translational and epigenetic web. Transcriptionally, oncogenic microRNAs (e.g., miR-150) strictly silence VHL, establishing deleterious feedback loops that hyperactivates EGFR/AKT and β-catenin signaling [123]. Post-translationally, VHL is aggressively degraded by overexpressed E3 ligases (e.g., FBXO22) and the Wnt-complex protein Daam2 [124, 125, 136]. Furthermore, phosphorylated Profilin-1 (inhibiting VHL binding to HIF-1α) and ID2 (sterically occlude the VHL-Elongin C complex) could shield HIF-1α from the recognition of VHL, therefore stabilizing the HIF and promoting survival during metabolic stress. Preclinical cell-line and xenograft studies indicate that VHL downregulation promotes cell survival, stemness, and invasion [124, 125, 136, 137]. Experimental VHL restoration rapidly reverses this malignant phenotype, induces sudden G0/G1 cell cycle arrest, downregulates anti-apoptotic Bcl-2, and represses critical glioma stem-like cell markers (such as CD133) by re-establishing JAK2/STAT3 inhibition [138, 139]. However, strategies aimed at restoring VHL function or targeting upstream regulators remain experimental, lacking clinical validation in glioblastoma. Hematological malignancies In hematological malignancies, VHL dysregulation is predominantly non-mutational, displaying distinct evidence tiers across subtypes. Retrospective cohort studies indicate that VHL promoter hypermethylation correlates with adverse clinical features, such as osteolytic bone lesions in multiple myeloma (MM) [126, 140], and higher International Prognostic Index scores and dismal survival in diffuse large B-cell lymphoma (DLBCL) [141], making it a potential predictive and prognostic biomarker. In MM, epigenetic ablation of VHL abolishes HIF-1α proteolysis, precipitating local angiogenesis and driving an acidic, hypoxic marrow niche. This microenvironmental rewiring favors malignant plasma cell survival [126]. Regarding DLBCL, in vitro models suggest that oncogenic miR-21 suppresses VHL post-transcriptionally. Pharmacological antagonism of miR-21 (e.g., via curcumin) successfully restabilizes VHL, restricting DLBCL proliferation and inducing apoptosis [127]. Beyond somatic silencing, a single-pedigree report proposed a multi-hit leukemogenesis model wherein germline VHL variants cooperate with acquired somatic mutations (e.g., BCOR, NF1) and genetic modifiers (e.g., ASXL3, CCR7) to drive phenotypic heterogeneity [142]. These findings expand the known phenotypic repertoire of VHL-related disorders, highlight the complex genotype-phenotype interplay, and offer insights for genetic counseling and clinical management of familial hematological disorders. HNSCC In head and neck squamous cell carcinoma (HNSCC), VHL dysregulation is non-mutational. Although chromosome 3p LOH encompassing the VHL locus is frequent in tongue SCC, VHL protein exhibits dynamic expression. Its cytoplasmic expression spatially expands during premalignant dysplasia and invasive carcinogenesis, tightly co-localizing with the basal proliferative marker CK17 [143, 144]. This aberrant accumulation establishes VHL as a distinct adjunctive histopathological biomarker for early dysplastic transformation, although its expression intensity progressively wanes during tumor dedifferentiation [144]. Preclinically, residual VHL is suppressed post-transcriptionally by oncogenic miR-21, unleashing downstream STAT3 and β-catenin cascades to drive tumor invasion. Pharmacological inhibition of STAT3 (e.g., using HJC0152) indirectly restores VHL levels and dismantles the STAT3/miR-21/VHL/β-catenin axis, restricting tumor growth and invasion in vitro and in orthotopic mouse models [128]. However, this therapeutic approach remains strictly preclinical and warrants further clinical validation. Therapeutic strategies: from inhibitors to degraders Translating the established mechanistic of VHL novel targets and pan-cancer landscapes into clinical applications encompasses two primary approaches: targeted SMIs exploiting VHL-deficient vulnerabilities and VHL-recruiting PROTACs. SMIs targeting novel substrates The identification of non-canonical VHL novel targets has unveiled new oncogenic pathways and therapeutic vulnerabilities in cancers, particularly ccRCC. Consequently, developing SMIs that target these pathways—either by inhibiting the target’s activity directly or by disrupting its upstream/downstream regulation—represents potential therapeutic frontiers (Table 3).Table 3Clinical trial progress of SMIs targeting VHL novel targetsInhibitor (target pathway)AdministrationTrial IDStudy designKey inclusion criteriaSample sizeStatusKey clinical insightsMomelotinib (TBK1/JAK1/2) [145]Oral (200 mg daily)NCT04173494 (MOMENTUM)Randomized (2:1), double-blind, active control. phase 3 trial comparing momelotinib vs danazol.Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.Momelotinib group: 130, danazol group: 65CompletedClinically significant improvements in myelofibrosis-associated symptoms, anemia, and spleen response vs danazol (25% vs 9% achieving ≥ 50% TSS reduction) with favourable safety.Momelotinib (TBK1/JAK1/2) [146]Oral (100–200 mg daily/bid)NCT02101021 (PDAC), NCT02258607 (NSCLC)Phase Ib/II dose-escalation and expansion studies evaluating momelotinib combined with chemotherapy or MEK inhibitor (trametinib).Previously untreated metastatic PDAC or metastatic KRAS-mutated NSCLC.21TerminatedFailed to demonstrate OS benefit in unselected solid tumors. Future oncology repurposing absolutely requires VHL-loss stratification to exploit TBK1 synthetic lethality.Amlexanox (TBK1/IKKε) [147]Oral (25-50 mg tid)NCT01842282 (phase II), NCT01975935 (phase II)Open-label safety run-in followed by randomized, double-blind, placebo-controlled proof-of-concept study.Obesity, type 2 diabetes, NAFLD.Amlexanox group: 21, placebo group: 21.CompletedModulates metabolic parameters, reverses insulin resistance, and reduces hepatic steatosis safely. Extensive preclinical efficacy across CRPC, CRC, and glioblastoma strongly supports oncology repurposing.Alisertib (AURKA inhibitor) [148]Oral (50 mg bid for 7 days followed by a break of 14 days in 21-day cycles)NCT01045421 (phase I/II)Open-label, multicenter, phase 1 dose escalation followed by 2-stage phase 2 expansion.Patients with advanced non-hematological malignancies (NSCLC, SCLC, breast, HNSCC, gastroesophageal) that had relapsed or was refractory to chemotherapy.249 (breast cancer: 53, SCLC: 60, NSCLC: 26, HNSCC: 55, gastro-oesophageal adenocarcinoma: 55).CompletedEstablished RP2D at 50 mg bid; demonstrated pan-solid tumor feasibility and preliminary activity, particularly those with breast cancer and SCLC.Alisertib (AURKA inhibitor) [149]Oral (50 mg bid on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle) with or without standard-dose fulvestrantNCT02860000 (TBCRC041 Phase II)Phase II randomized trial evaluating alisertib alone or combined with fulvestrant.Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)-negative MBC who were previously treated with fulvestrant.96 (alisertib monotherapy: 47, alisertib+fulvestrant: 49).CompletedDemonstrated ORR of ~20% in endocrine-resistant cohorts. The overall safety profile was tolerable. Adding fulvestrant to treatment with alisertib did not increase ORR or PFS.Alisertib + Paclitaxel (AURKA inhibitor) [150, 151]NCT01091428: Oral (alsertib 40 mg bid and 3 days on and 4 days off for 3 weeks) + Intravenous (paclitaxel (60 mg/m2 on days 1, 8, and 15, or weekly paclitaxel 80 mg/m2 in 28-day cycles).NCT01091428, NCT02187991Open-label phase 1 and phase 2 randomized trials evaluating alisertib plus paclitaxel vs paclitaxel alone.NCT01091428: Advanced/recurrent breast cancer or recurrent ovarian cancer. NCT02187991: Patients with ER-positive and ERBB2-negative or triple-negative metastatic breast cancer (MBC).NCT01091428: phase 1: 191. Phase 2: 142 (paclitaxel alone: 69, alisertib plus paclitaxel:73). NCT02187991: 174 (paclitaxel: 86, paclitaxel plus alisertib:88).CompletedPFS significantly favored the alisertib plus paclitaxel combination (median: 10.2 months) over paclitaxel alone (median: 7.1 months) across multiple cohorts; manageable toxicity with dose reductions.Alisertib + Sapanisertib (AURKA inhibitor + TORC1/2) [152]Oral (alisertib 30 mg tid on days 1–7 in a 21-day cycle and sapanisertib 2 mg qd)-Phase Ib expansion cohort evaluating alisertib and dual TORC1/2 inhibitor SapanisertibPatients with histologically confirmed solid tumor that was incurable or refractory to standard therapy, or for which no standard therapy exists, including pancreatic adenocarcinoma.Solid tumor expansion cohort: 20 (alisertib lead-in: 10, sapanisertib lead-in: 10), pancreatic cancer expansion cohort: 11.CompletedEstablished safety, feasibility, and preliminary synergistic anti-tumor activity of combined AURKA and mTORC1/2 inhibition.Opaganib/ABC294640 (SPHK2 inhibitor) [153]Administered orally in sequential cohorts: 250 mg qd, 250 mg bid, 500 mg bid, and 750 mg bid, continuously in cycles of 28 days.NCT01488513 (Phase I)Open-label, sequential cohort, dose-escalation phase I study.Advanced solid tumors.21 received ABC294640.CompletedFirst-in-class SPHK2 inhibitor altering systemic sphingolipid rheostat; established safe profile, maximum tolerated dose, and biological capacity to reduce plasma S1P levels in humans. At 500 mg bid, ABC294640 is well tolerated and achieves biologically relevant plasma concentrations.Opaganib/ABC294640 (SPHK2 inhibitor) [154]Oral (250–750 mg bid, continuously in cycles of 28 days)NCT02757326 (Phase I)Open-label phase I dose-escalation evaluating safety, MTD, and pharmacokinetics/pharmacodynamics.Relapsed/refractory multiple myeloma (RRMM) previously treated with immunomodulatory drugs and proteasome inhibitors.13CompletedEvaluated SPHK2 inhibition combined with an autophagy inhibitor to counteract cancer cell survival mechanisms.Opaganib/ABC294640 (SPHK2 inhibitor)Part 1: Oral (500 mg bid, continuously in cycles of 28 days).Part 2: accelerate HCQ dose-escalation run-in starting with a dose of 200 mg qd.NCT03377179 (phase IIA)Single-arm phase IIA clinical study of ABC294640 alone and in combination with hydroxychloroquine (HCQ).Advanced intra-hepatic, perihilar and extra-hepatic unresectable cholangiocarcinoma, receiving no more than 2 prior treatments with systemic anti-neoplastic therapy.65CompletedEvaluated SPHK2 inhibition combined with an autophagy inhibitor to counteract cancer cell survival mechanisms.Bortezomib (LONP1 inhibitor) [155]Intravenous (1.3 - 1.5 mg/m2)-Open-label Phase II evaluating tumor response and toxicity of bortezomib.Metastatic RCC; 62% prior nephrectomy.37CompletedMonotherapy yielded an 11% partial response. Insufficient for routine unselected use, highlighting the need for VHL-stratification.Bortezomib (LONP1 inhibitor)Intravenous (1.3 mg/m2) over 3–5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 coursesNCT00276614 (Phase II)Phase II trial assessing objective response rate.Metastatic non-ccRCC, expressing wild-type VHL gene.4CompletedExplored efficacy in non-ccRCC histologies.Bortezomib + Bevacizumab (LONP1 + VEGF inhibitor)Bevacizumab 15 mg/kg on day 1 with bortezomib (schedule A: 1.0 or 1.3; schedule B: 1.6 or 1.8 mg/m2) on days 1, 4, 8 and 11 every 21 daysNCT00184015 (Phase I and II)Phase I trial assessing safety and tolerability of combination of bevacizumab and bortezomib. Phase II trial assessing efficacy of combination therapy based on the doses and schedules in phase 1.Distant metastatic (TxNxM1) or locally recurrent RCC not amenable to cure by surgical or other means.50UnknownEvaluated dual targeting of the proteasome and angiogenesis.Bortezomib + Sorafenib (LONP1 inhibitor + TKI) [156]Intravenous (bortezomib: 1.0 mg/m2) + oral (sorafenib: 200 mg bid) on days 1, 4, 8, and 11 every 21 daysNCT01100242 (Phase II)Open-label Phase II evaluating the efficacy and toxicity of sorafenib+bortezomibAdult patients with ccRCC with no prior chemotherapy.17TerminatedThe combination of sorafenib and bortezomib was well tolerated. The trial was halted for futility (response rate: 6%); comparable to sorafenib monotherapy. Table 3Clinical trial progress of SMIs targeting VHL novel targetsInhibitor (target pathway)AdministrationTrial IDStudy designKey inclusion criteriaSample sizeStatusKey clinical insightsMomelotinib (TBK1/JAK1/2) [145]Oral (200 mg daily)NCT04173494 (MOMENTUM)Randomized (2:1), double-blind, active control. phase 3 trial comparing momelotinib vs danazol.Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.Momelotinib group: 130, danazol group: 65CompletedClinically significant improvements in myelofibrosis-associated symptoms, anemia, and spleen response vs danazol (25% vs 9% achieving ≥ 50% TSS reduction) with favourable safety.Momelotinib (TBK1/JAK1/2) [146]Oral (100–200 mg daily/bid)NCT02101021 (PDAC), NCT02258607 (NSCLC)Phase Ib/II dose-escalation and expansion studies evaluating momelotinib combined with chemotherapy or MEK inhibitor (trametinib).Previously untreated metastatic PDAC or metastatic KRAS-mutated NSCLC.21TerminatedFailed to demonstrate OS benefit in unselected solid tumors. Future oncology repurposing absolutely requires VHL-loss stratification to exploit TBK1 synthetic lethality.Amlexanox (TBK1/IKKε) [147]Oral (25-50 mg tid)NCT01842282 (phase II), NCT01975935 (phase II)Open-label safety run-in followed by randomized, double-blind, placebo-controlled proof-of-concept study.Obesity, type 2 diabetes, NAFLD.Amlexanox group: 21, placebo group: 21.CompletedModulates metabolic parameters, reverses insulin resistance, and reduces hepatic steatosis safely. Extensive preclinical efficacy across CRPC, CRC, and glioblastoma strongly supports oncology repurposing.Alisertib (AURKA inhibitor) [148]Oral (50 mg bid for 7 days followed by a break of 14 days in 21-day cycles)NCT01045421 (phase I/II)Open-label, multicenter, phase 1 dose escalation followed by 2-stage phase 2 expansion.Patients with advanced non-hematological malignancies (NSCLC, SCLC, breast, HNSCC, gastroesophageal) that had relapsed or was refractory to chemotherapy.249 (breast cancer: 53, SCLC: 60, NSCLC: 26, HNSCC: 55, gastro-oesophageal adenocarcinoma: 55).CompletedEstablished RP2D at 50 mg bid; demonstrated pan-solid tumor feasibility and preliminary activity, particularly those with breast cancer and SCLC.Alisertib (AURKA inhibitor) [149]Oral (50 mg bid on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle) with or without standard-dose fulvestrantNCT02860000 (TBCRC041 Phase II)Phase II randomized trial evaluating alisertib alone or combined with fulvestrant.Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)-negative MBC who were previously treated with fulvestrant.96 (alisertib monotherapy: 47, alisertib+fulvestrant: 49).CompletedDemonstrated ORR of ~20% in endocrine-resistant cohorts. The overall safety profile was tolerable. Adding fulvestrant to treatment with alisertib did not increase ORR or PFS.Alisertib + Paclitaxel (AURKA inhibitor) [150, 151]NCT01091428: Oral (alsertib 40 mg bid and 3 days on and 4 days off for 3 weeks) + Intravenous (paclitaxel (60 mg/m2 on days 1, 8, and 15, or weekly paclitaxel 80 mg/m2 in 28-day cycles).NCT01091428, NCT02187991Open-label phase 1 and phase 2 randomized trials evaluating alisertib plus paclitaxel vs paclitaxel alone.NCT01091428: Advanced/recurrent breast cancer or recurrent ovarian cancer. NCT02187991: Patients with ER-positive and ERBB2-negative or triple-negative metastatic breast cancer (MBC).NCT01091428: phase 1: 191. Phase 2: 142 (paclitaxel alone: 69, alisertib plus paclitaxel:73). NCT02187991: 174 (paclitaxel: 86, paclitaxel plus alisertib:88).CompletedPFS significantly favored the alisertib plus paclitaxel combination (median: 10.2 months) over paclitaxel alone (median: 7.1 months) across multiple cohorts; manageable toxicity with dose reductions.Alisertib + Sapanisertib (AURKA inhibitor + TORC1/2) [152]Oral (alisertib 30 mg tid on days 1–7 in a 21-day cycle and sapanisertib 2 mg qd)-Phase Ib expansion cohort evaluating alisertib and dual TORC1/2 inhibitor SapanisertibPatients with histologically confirmed solid tumor that was incurable or refractory to standard therapy, or for which no standard therapy exists, including pancreatic adenocarcinoma.Solid tumor expansion cohort: 20 (alisertib lead-in: 10, sapanisertib lead-in: 10), pancreatic cancer expansion cohort: 11.CompletedEstablished safety, feasibility, and preliminary synergistic anti-tumor activity of combined AURKA and mTORC1/2 inhibition.Opaganib/ABC294640 (SPHK2 inhibitor) [153]Administered orally in sequential cohorts: 250 mg qd, 250 mg bid, 500 mg bid, and 750 mg bid, continuously in cycles of 28 days.NCT01488513 (Phase I)Open-label, sequential cohort, dose-escalation phase I study.Advanced solid tumors.21 received ABC294640.CompletedFirst-in-class SPHK2 inhibitor altering systemic sphingolipid rheostat; established safe profile, maximum tolerated dose, and biological capacity to reduce plasma S1P levels in humans. At 500 mg bid, ABC294640 is well tolerated and achieves biologically relevant plasma concentrations.Opaganib/ABC294640 (SPHK2 inhibitor) [154]Oral (250–750 mg bid, continuously in cycles of 28 days)NCT02757326 (Phase I)Open-label phase I dose-escalation evaluating safety, MTD, and pharmacokinetics/pharmacodynamics.Relapsed/refractory multiple myeloma (RRMM) previously treated with immunomodulatory drugs and proteasome inhibitors.13CompletedEvaluated SPHK2 inhibition combined with an autophagy inhibitor to counteract cancer cell survival mechanisms.Opaganib/ABC294640 (SPHK2 inhibitor)Part 1: Oral (500 mg bid, continuously in cycles of 28 days).Part 2: accelerate HCQ dose-escalation run-in starting with a dose of 200 mg qd.NCT03377179 (phase IIA)Single-arm phase IIA clinical study of ABC294640 alone and in combination with hydroxychloroquine (HCQ).Advanced intra-hepatic, perihilar and extra-hepatic unresectable cholangiocarcinoma, receiving no more than 2 prior treatments with systemic anti-neoplastic therapy.65CompletedEvaluated SPHK2 inhibition combined with an autophagy inhibitor to counteract cancer cell survival mechanisms.Bortezomib (LONP1 inhibitor) [155]Intravenous (1.3 - 1.5 mg/m2)-Open-label Phase II evaluating tumor response and toxicity of bortezomib.Metastatic RCC; 62% prior nephrectomy.37CompletedMonotherapy yielded an 11% partial response. Insufficient for routine unselected use, highlighting the need for VHL-stratification.Bortezomib (LONP1 inhibitor)Intravenous (1.3 mg/m2) over 3–5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 coursesNCT00276614 (Phase II)Phase II trial assessing objective response rate.Metastatic non-ccRCC, expressing wild-type VHL gene.4CompletedExplored efficacy in non-ccRCC histologies.Bortezomib + Bevacizumab (LONP1 + VEGF inhibitor)Bevacizumab 15 mg/kg on day 1 with bortezomib (schedule A: 1.0 or 1.3; schedule B: 1.6 or 1.8 mg/m2) on days 1, 4, 8 and 11 every 21 daysNCT00184015 (Phase I and II)Phase I trial assessing safety and tolerability of combination of bevacizumab and bortezomib. Phase II trial assessing efficacy of combination therapy based on the doses and schedules in phase 1.Distant metastatic (TxNxM1) or locally recurrent RCC not amenable to cure by surgical or other means.50UnknownEvaluated dual targeting of the proteasome and angiogenesis.Bortezomib + Sorafenib (LONP1 inhibitor + TKI) [156]Intravenous (bortezomib: 1.0 mg/m2) + oral (sorafenib: 200 mg bid) on days 1, 4, 8, and 11 every 21 daysNCT01100242 (Phase II)Open-label Phase II evaluating the efficacy and toxicity of sorafenib+bortezomibAdult patients with ccRCC with no prior chemotherapy.17TerminatedThe combination of sorafenib and bortezomib was well tolerated. The trial was halted for futility (response rate: 6%); comparable to sorafenib monotherapy. Clinical trial progress of SMIs targeting VHL novel targets Part 1: Oral (500 mg bid, continuously in cycles of 28 days). Part 2: accelerate HCQ dose-escalation run-in starting with a dose of 200 mg qd. TBK1 inhibitors In VHL-deficient ccRCC, constitutive TBK1 hyperactivation has been proposed preclinically as a synthetic lethal vulnerability, offering rationales for repurposing clinical-stage TBK1 inhibitors. Momelotinib, an FDA-approved dual JAK/TBK1 inhibitor with clinical success in hematological settings (e.g., the phase III MOMENTUM trial for myelofibrosis) [145], conferred limited survival benefits in unselected solid tumor trials [e.g., NSCLC and pancreatic ductal adenocarcinoma (PDAC)] [146]. It’s potentially attributable to the lack of biomarker-driven patient selection (e.g., VHL status). Similarly, amlexanox, a dual IKKε/TBK1 inhibitor evaluated in metabolic disorders, suppresses TBK1 activity to disrupt p62-driven oncogenic signaling downstream of VHL loss [147, 157, 158]. Recent preclinical profiling reveals its pleiotropic anticancer efficacy in vitro and in xenograft models across diverse malignancies (e.g., colorectal cancer, glioblastoma and castration-resistant PCa) via the disruption of Hippo/LATS signaling and Rad51-dependent DNA repair [159]. However, its clinical translation is constrained by potential off-target toxicities, narrow therapeutic windows, and an absence of oncological clinical trial validation. SPHK1 inhibitors In VHL-deficient malignancies, pathological stabilization of the substrate SFMBT1 upregulates SPHK1 and alters sphingolipid metabolism toward aggressive proliferation [27]. Lacking direct SFMBT1 inhibitors, pharmacological blockade of downstream SPHK signaling offers a rational therapeutic bypass. Preclinically, SPHK1 inhibitors (e.g., PF-543) and SPHK2 inhibitor opaganib (ABC294640) suppress tumor cell proliferation and growth in cell-line and patient-derived xenograft models [160, 161]. Clinically, opaganib has demonstrated safety and systemic pro-survival S1P reduction in phase I/II trials for advanced solid tumors and refractory MM [153, 154]. However, targeting SPHK signaling in VHL-deficient tumors remains hypothetical and preclinical, currently lacking clinical validation in VHL-stratified cohorts and limited by potential metabolic redundancy and dose-limiting toxicities. AURKA inhibition In VHL-deficient ccRCC, loss of VHL function preclinically correlates with increased sensitivity to alisertib (MLN8237), a selective, orally bioavailable ATP-competitive AURKA inhibitor [162]. Concomitant targeting of AURKA and downstream nodes, such as the E3 ligase SKP2 (e.g., SZL-P1-41), demonstrates synergistic growth suppression in ccRCC cell-line and xenograft models [163]. Clinically, alisertib has been evaluated in non-VHL-stratified solid tumor trials including paclitaxel-resistant ovarian cancer, endocrine/CDK4/6i-resistant metastatic breast cancer (e.g., TBCRC041) and refractory pancreatic adenocarcinoma. Primarily in combination regimens with chemotherapy or mTOR inhibitors, it demonstrated disease stabilization and partial responses (PRs), though frequently constrained by dose-limiting hematologic toxicities such as neutropenia and leukopenia [150, 152]. Thus, alisertib has exhibited good potential in treating advanced tumors, currently requiring clinical trial verification in VHL-selected patient cohorts. LONP1-TFAM-related SMIs In VHL-deficient carcinomas, the mitochondrial matrix protease LONP1 aberrantly degrades the transcription factor TFAM, enforcing the Warburg effect and suppressing oxidative phosphorylation [48]. Although bortezomib (26S proteasome inhibitor) lacks selectivity for LONP1 and exerts broad proteasomal off-target effects, it preclinically stabilizes TFAM, modulates NF-κB signaling, and powerfully resensitizes highly refractory tumors to TKIs in VHL-deficient preclinical models [164]. It played significant roles as therapeutic drugs for various cancers. We mainly focused on the progress in unselected metastatic RCC treatment. Multiple early-phase evaluations of bortezomib—either as monotherapy or combined with sorafenib/bevacizumab—yielded minimal activity [155, 156], confounded by severe proteasome-related toxicities and a lack of biomarker stratification. Selective LONP1 inhibitors remain in early preclinical development; thus, therapeutic exploitation of the VHL-LONP1-TFAM axis in oncology remains an unvalidated hypothesis requiring clinical verification. Harnessing VHL as a tool: PROTACs In contrast to therapeutic strategies exploiting VHL loss in VHL-deficient malignancies such as ccRCC, VHL-recruiting PROTACs strictly depend on intact, functional VHL machinery. PROTAC represents a transformative class of heterobifunctional molecules engineered to hijack the ubiquitin-proteasome system for targeted chemical knockdown. These heterobifunctional molecules tether a protein of interest (POI) binder to a high-affinity VHL ligand, facilitating ternary complex (POI-PROTAC-VHL) assembly and subsequent proteasomal degradation of the target [165]. Driven by the favorable structural fidelity and physicochemical properties of VHL-ligands, VHL represents one of the most widely utilized E3 ligases in targeted protein degradation alongside Cereblon [166]. In VHL-proficient contexts, VHL-recruiting PROTACs are characterized by the following advantages (Fig. 4): (1) Substoichiometric event-driven pharmacology and expanded druggable proteome scope: Unlike occupancy-driven SMIs requiring deep active-site pockets and sustained systemic exposure, VHL-recruiting PROTACs operate via event-driven mechanisms. Transient binding to accessible surface pockets triggers target ubiquitination, enabling target depletion at substoichiometric concentrations and theoretically lowering dose-dependent off-target toxicity [167, 168]. Moreover, this catalytic turnover enables the depletion of non-enzymatic scaffolding proteins and historically “undruggable” targets, including p38α, RAS, and selected transcription factors [167, 169, 170]. (2) Enhanced selectivity: Different from non-cooperative ternary assemblies, VHL-recruiting PROTACs can form thermodynamically stable, cooperative ternary complexes (POI-PROTAC-VHL) stabilized by spatial protein-protein interactions. This thermodynamic stability improves degradation selectivity and efficiency, as demonstrated by isoform-specific SGK3 degradation in vitro [166, 171]. (3) Overcoming resistance: Catalytic, event-driven degradation can bypass target point mutations and protein accumulation that impair SMI binding [169]. Preclinically, VHL-recruiting PROTACs have demonstrated efficacy against SMI-resistant variants, such as BCR-ABL mutants [172]. Furthermore, targeted degradation can overcome resistance driven by target overexpression or secondary mutations, as observed with anaplastic lymphoma kinase (ALK) degraders in preclinical NSCLC models refractory to conventional ALK inhibitors (e.g., ceritinib, lorlatinib) [173]. (4) Concomitant pathway modulation: Occupation of the VHL binding pocket by PROTACs can competitively stabilize physiological VHL substrates while degrading the targeted pathogenic protein. For instance, a Smad3-targeting PROTAC demonstrated anti-fibrotic activity via Smad3 degradation alongside cytoprotection via concomitant HIF-2α stabilization in rodent models [174].Fig. 4Illustration of principles and advantages of VHL-recruiting PROTACs. Created with BioRender.com/22s0pra Illustration of principles and advantages of VHL-recruiting PROTACs. Created with BioRender.com/22s0pra Propelled by these mechanistic advantages, VHL-PROTACs are translating from preclinical validation into clinical reality. To date, at least four VHL-PROTACs are undergoing clinical evaluation (Table 4), predominantly targeting established oncological indications.Table 4The research progress of VHL-recruiting PROTACs in clinical trials for cancer therapyDrug Candidate (Target)AdministrationClinical PhaseTrial IDStudy DesignKey Inclusion CriteriaSample sizeStatusKey Clinical InsightsDT2216 (BCL-XL) [175]Intravenous (biw) in a 28-day cycle, maximum duration of 12 months. Dose cohorts ranged from 0.04 mg/kg to 0.4 mg/kg.Phase 1/1bNCT04886622 (phase 1 first-in-human); NCT06964009 (phase 1b combination)An open-lable dose escalation study using a 3 + 3 design to determine the MTD and RP2D.Adult patients with advanced relapsed or refractory (R/R) malignancies have progressed on standard-of-care treatments. Specific focus on solid tumors (including SCLC) and lymphomas (specifically T-cell lymphoma, TCL).20Active; phase 1b recruitingPlatelet-Sparing: 20% SD rate in a heavily pre-treated population (median prior therapies > 3, median duration of SD: 107 days). Solves navitoclax toxicity. Transient Gr4 thrombocytopenia (cycle 1). RP2D: 0.4 mg/kg. Orphan Drug Designation for T-cell lymphoma and SCLC, and Fast Track Designation for relapsed/refractory peripheral TCL and cutaneous TCL.KT-333 (STAT3)Intravenous (qw) on day 1, 8, 15 and 22 (28-day cycle).Phase 1a/1bNCT05225584Phase 1a: dose escalation (accelerated titration followed by 3 + 3) to define the MTD/RP2D.Phase 1b: Dose expansion in specific indications.Patients with B- and T-cell lymphomas, HL and advanced solid tumors R/R to at least two prior systemic therapies, and LGL-L and T-cell prolymphocytic leukemia R/R to at least one prior therapy.56Dose expansion ongoingFirst transcription factor degrader: Robust STAT3 degradation (>90%). Downregulation of STAT3 target genes such as SOCS3 and the upregulation of inflammatory markers like IFN-γ in the blood. CRs in cHL and STAT3-mutated NK-cell lymphoma, multiple PRs in cutaneous TCL.ASP3082 (KRAS G12D)Intravenous (qw) over a 21-day cycle.Phase 1NCT05382559Dose-escalation and dose-expansion study.Adults with unresectable or metastatic KRAS G12D-positive solid tumors (Confirmed KRAS G12D mutation in tumor tissue or ctDNA).681RecruitingFirst KRAS G12D Degrader: Predicted lowest dose for clinical efficacy: 100 mg. At high dose: 300 mg, ORR: 33.3% (3 PR/7 pancreatic cancer, 1 PR/4 NSCLC, 0 PR/1 CRC), DCR: 75% (5/7 pancreatic cancer, 4/4 NSCLC, 0/1 CRC).PRT3789 (SMARCA2)Intravenous (qw).Phase 1NCT05639751NCT06682806Phase 1 (monotherapy & Docetaxel Combo) dose escalation study with backfill cohorts added at active doses. phase 2 (Pembrolizumab Combo).Patients with any solid tumor and any SMARCA4 mutation (loss-of-function or missense).Phase 1: 135. Phase 2: 6.Phase 1: completed. Phase 2 Terminated.Synthetic Lethality: Selective degradation of SMARCA2. RECIST PR, tumor shrinkage and prolonged SD (longer than response to most recent therapy) in patients with advanced, heavily pretreated esophageal cancer and NSCLC. No DLTs or study drug-related SAEs. Table 4The research progress of VHL-recruiting PROTACs in clinical trials for cancer therapyDrug Candidate (Target)AdministrationClinical PhaseTrial IDStudy DesignKey Inclusion CriteriaSample sizeStatusKey Clinical InsightsDT2216 (BCL-XL) [175]Intravenous (biw) in a 28-day cycle, maximum duration of 12 months. Dose cohorts ranged from 0.04 mg/kg to 0.4 mg/kg.Phase 1/1bNCT04886622 (phase 1 first-in-human); NCT06964009 (phase 1b combination)An open-lable dose escalation study using a 3 + 3 design to determine the MTD and RP2D.Adult patients with advanced relapsed or refractory (R/R) malignancies have progressed on standard-of-care treatments. Specific focus on solid tumors (including SCLC) and lymphomas (specifically T-cell lymphoma, TCL).20Active; phase 1b recruitingPlatelet-Sparing: 20% SD rate in a heavily pre-treated population (median prior therapies > 3, median duration of SD: 107 days). Solves navitoclax toxicity. Transient Gr4 thrombocytopenia (cycle 1). RP2D: 0.4 mg/kg. Orphan Drug Designation for T-cell lymphoma and SCLC, and Fast Track Designation for relapsed/refractory peripheral TCL and cutaneous TCL.KT-333 (STAT3)Intravenous (qw) on day 1, 8, 15 and 22 (28-day cycle).Phase 1a/1bNCT05225584Phase 1a: dose escalation (accelerated titration followed by 3 + 3) to define the MTD/RP2D.Phase 1b: Dose expansion in specific indications.Patients with B- and T-cell lymphomas, HL and advanced solid tumors R/R to at least two prior systemic therapies, and LGL-L and T-cell prolymphocytic leukemia R/R to at least one prior therapy.56Dose expansion ongoingFirst transcription factor degrader: Robust STAT3 degradation (>90%). Downregulation of STAT3 target genes such as SOCS3 and the upregulation of inflammatory markers like IFN-γ in the blood. CRs in cHL and STAT3-mutated NK-cell lymphoma, multiple PRs in cutaneous TCL.ASP3082 (KRAS G12D)Intravenous (qw) over a 21-day cycle.Phase 1NCT05382559Dose-escalation and dose-expansion study.Adults with unresectable or metastatic KRAS G12D-positive solid tumors (Confirmed KRAS G12D mutation in tumor tissue or ctDNA).681RecruitingFirst KRAS G12D Degrader: Predicted lowest dose for clinical efficacy: 100 mg. At high dose: 300 mg, ORR: 33.3% (3 PR/7 pancreatic cancer, 1 PR/4 NSCLC, 0 PR/1 CRC), DCR: 75% (5/7 pancreatic cancer, 4/4 NSCLC, 0/1 CRC).PRT3789 (SMARCA2)Intravenous (qw).Phase 1NCT05639751NCT06682806Phase 1 (monotherapy & Docetaxel Combo) dose escalation study with backfill cohorts added at active doses. phase 2 (Pembrolizumab Combo).Patients with any solid tumor and any SMARCA4 mutation (loss-of-function or missense).Phase 1: 135. Phase 2: 6.Phase 1: completed. Phase 2 Terminated.Synthetic Lethality: Selective degradation of SMARCA2. RECIST PR, tumor shrinkage and prolonged SD (longer than response to most recent therapy) in patients with advanced, heavily pretreated esophageal cancer and NSCLC. No DLTs or study drug-related SAEs. The research progress of VHL-recruiting PROTACs in clinical trials for cancer therapy Phase 1a: dose escalation (accelerated titration followed by 3 + 3) to define the MTD/RP2D. Phase 1b: Dose expansion in specific indications. NCT05639751 NCT06682806 DT2216 B-cell lymphoma-extra-large (BCL-XL), a pivotal anti-apoptotic protein, drives oncogenesis by sequestering pro-apoptotic effectors (e.g., BIM, BAX) to evade apoptosis. BCL-XL is frequently overexpressed in various hematologic (e.g., T-cell lymphomas, TCLs) and solid malignancies (e.g., small cell lung cancer, SCLC) [176]. Conventional BCL-XL SMIs (e.g., navitoclax) are constrained by dose-limiting on-target thrombocytopenia due to platelet reliance on BCL-XL for survival [177]. To widen this narrow therapeutic window, DT2216 was engineered as a first-in-class BCL-XL PROTAC that recruits wild-type VHL. Because mature platelets express low levels of VHL, DT2216 selectively induces BCL-XL degradation and triggers BAX/BAK-dependent apoptosis in VHL-proficient tumor cells while sparing platelets [178, 179]. Preclinically, in post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML)—a high-risk subset strictly dependent on BCL-XL—DT2216 eradicates CD34+ leukemic stem cells. DT2216 exhibited broad synergistic potential, which resensitizes refractory melanoma to BRAF/MEK targeted therapies [180], synergizes with DHODH inhibitors in PDAC [181], and primes chromophobe RCC for ferroptosis-induced cell death [182]. In ongoing phase I/Ib trials, DT2216 exhibited stable pharmacokinetic profiles, reduced platelet toxicity (transient, reversible thrombocytopenia) and preliminary antitumor activity [stable disease (SD) in 20% patients, median OS: 7.9 months] in refractory malignancies [175]. Though DT2216 has secured FDA Orphan Drug and Fast Track designations for TCL and SCLC, its clinical translation will depend on identifying biomarkers of BCL-XL dependency and combining with MCL-1 or BCL-2 inhibitors to prevent anti-apoptotic signaling redundancy. KT-333 STAT3 is an oncogenic master regulator driving tumor proliferation, survival, and immunosuppressive microenvironment via PD-L1 upregulation. As a transcription factor lacking deep hydrophobic enzymatic pockets, STAT3 has historically proven difficult to target with conventional SMIs and was considered “undruggable”. To overcome this limitation, KT-333 was developed as a first-in-class VHL-PROTAC that recruits wild-type VHL to induce ubiquitin-proteasomal degradation of STAT3, bypassing the need for high-affinity active site occupancy [183, 184]. In an ongoing phase I trial in relapsed/refractory lymphomas and solid tumors (NCT05225584, n = 51), KT-333 demonstrated up to 99% target reduction in peripheral blood and tumor biopsies, abolishing downstream oncogenic signaling (e.g., SOCS3) and inducing IFN-γ transcriptional signature. KT-333 achieved CRs in classic Hodgkin lymphoma (cHL) and STAT3-mutated NK-cell lymphoma, alongside multiple PRs in cutaneous TCL. It also exhibits manageable safety profiles with main toxicities including stomatitis and fatigue [185]. Validating phase II durability remains crucial next steps. ASP3082 Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) drive approximately 30% of all malignancies. As the most common (29%) mutation in KRAS-mutated cancer, KRAS-G12D has the highest prevalence across diverse carcinomas such as PDAC and colorectal cancer [186]. However, unlike KRAS-G12C variants targeted by covalent inhibitors, KRAS-G12D lacks a reactive cysteine residue, hindering conventional SMIs [186, 187]. ASP3082 was developed as a first-in-class VHL-recruiting PROTAC that achieves durable suppression of downstream effectors (e.g., p-ERK, p-AKT) with exquisite selectivity over wild-type KRAS. Preclinically, despite high lipophilicity and plasma protein binding that necessitate intermittent intravenous administration, ASP3082 effectively induced tumor regression in xenograft models [188]. In an ongoing phase I trial in advanced solid tumors (NCT05382559), ASP3082 demonstrated preliminary clinical activity with reversible transaminase (ALT/AST) elevations as primary toxicities. At the 300 mg dose level, it achieved a 33.3% ORR and a 75.0% disease control rate (DCR), delivering PRs in refractory PDAC and NSCLC [189]. Overcoming high plasma protein binding to optimize free drug exposure and developing strategies to manage intravenous delivery demands represent critical priorities. PRT3789 Aberrations within the SWI/SNF (BAF) chromatin remodeling complex drive approximately 20% of human malignancies, altering the TME and modulating therapeutic responses to ICIs. The catalytic ATPase activity of this complex is governed by mutually exclusive paralogs: SMARCA2 or SMARCA4. In many cancers (e.g., NSCLC, esophageal) harboring loss-of-function mutations in SMARCA4, cells become dependent on its paralog SMARCA2 for survival, establishing a synthetic lethal vulnerability [190]. PRT3789 was engineered as a first-in-class VHL-recruiting PROTAC that selectively degrades SMARCA2 over SMARCA4 (>1000-fold selectivity). This specificity is governed by a slow ternary complex dissociation rate, which directs polyubiquitination strictly to K1405—a residue located on an extended loop unique to SMARCA2 and absent in SMARCA4 paralog [191]. Preclinically, PRT3789 demonstrated selective SMARCA2 depletion, inducing cell death in SMARCA4-deficient models with a weekly intravenous dosing schedule supported by durable pharmacodynamic suppression [191]. In ongoing phase I trials in advanced SMARCA4-mutated solid tumors, PRT3789 showed preliminary clinical activity. It achieved RECIST-confirmed PRs, tumor shrinkage and prolonged SDs in heavily pretreated NSCLC and esophageal carcinomas with a favorable safety profile [192]. Future clinical implementation hinges on precise patient selection for complete SMARCA4 loss to account for intratumoral heterogeneity and exploring synergistic regimens with epigenetic regulators. While VHL-PROTACs present distinct pharmacological opportunities, critical biological and translational limitations exist. First, because catalytic degradation mandates an operational VCB-CR complex, these degraders are applicable primarily to VHL-proficient tumors. Conversely, VHL loss, mutation, or genomic inactivation represents a primary intrinsic or acquired resistance mechanism [170, 193]. Second, clinical translation is hindered by unfavorable physicochemical properties (high molecular weight, extensive polar surface area) that impair membrane permeability and oral bioavailability [194], as well as dose-dependent “hook effects” at high systemic exposures that attenuate ternary complex assembly in vivo [170, 171]. Third, because ubiquitination requires cooperative protein-protein interactions rather than simple binding affinity, empirical design is inefficient. Rational optimization increasingly relies on integrated structural biology and computational modeling platforms (e.g., PRosettaC) [195]. Furthermore, prolonged degradation pressure in preclinical models can select for point mutations at the ternary interface or somatic alterations in core ligase machinery [168, 170]. Crucially, current therapeutic claims derive predominantly from in vitro and animal models. Further rigorous validation is required to establish their human safety, therapeutic index, and clinical efficacy. Establishing biomarker-driven patient selection—specifically pre-screening for functional VHL status—will be mandatory to guide clinical development [168, 169]. Discussion and perspective While intercepting the canonical VHL-HIF axis (e.g., TKIs, ICIs, or HIF-2α inhibitors) has improved advanced ccRCC management, intrinsic non-responsiveness and acquired resistance in a subset of tumors remain major clinical challenges [14, 196, 197]. Accumulating evidence indicates that VHL functions beyond hypoxia regulation by interacting with non-HIF targets across epigenetic modulation (e.g., ZHX2, SETDB1, METTL3/METTL14), metabolic reprogramming (e.g., NDRG3, TFAM), ECM and cytoskeletal architecture regulation (e.g., fibronectin, COL4A2), and immune modulation (e.g., TBK1). The supporting evidence across these novel targets varies from direct biochemical ubiquitination to downstream correlative observations. By systematically mapping the expanding universe of non-HIF substrates, this review redefines VHL as a pleiotropic hub that coordinates proteostasis and cellular homeostasis. Furthermore, non-canonical VHL interactions extend to broad pan-cancer contexts. For example, VHL-mediated polyubiquitination of UBE3B suppresses breast cancer growth and metastasis in preclinical cell-line and xenograft models [60]. Therefore, shedding light on these novel VHL targets is important for redefining VHL-mediated proteostasis and pioneering next-generation therapies across both ccRCC and other malignancies. These targets represent merely a fraction of emerging therapeutic vulnerabilities ripe. Integrating these findings into the broader oncology research context demands a balanced evaluation of both established and emerging pathways to construct more comprehensive molecular frameworks. Translating these non-HIF mechanisms into clinical interventions presents distinct opportunities and challenges. In VHL-deficient tumors, targeting unshielded non-HIF downstream effectors (e.g., opaganib, alisertib) offers candidate salvage strategies. Conversely, in VHL-proficient malignancies, hijacking operational VHL via PROTACs (e.g., DT2216, KT-333) enables targeted degradation of oncogenic drivers. Nevertheless, clinical realization across both modalities faces substantial hurdles, including pharmacokinetic constraints, potential toxicities, intratumoral heterogeneity, and acquired resistance. Most advances remain at the preclinical or early-phase evaluation stage and must be viewed with cautious optimism, as the heterogeneity of cancer and the complexity of VHL target interactions necessitate rigorous validation. Future progress requires further investigation in robust translational models alongside biomarker-driven patient stratification to verify VHL functional status and target dependency. Conclusion This review delineates the evolution of VHL biology from a canonical HIF oxygen sensor to a broader regulator of proteostasis, establishing how non-HIF target networks and dual therapeutic modalities expand the oncology landscape—SMIs targeting non-HIF effectors in VHL-deficient tumors and VHL-recruiting PROTACs in VHL-proficient tumors. Fully realizing this translational potential requires addressing some major unresolved questions: (1) Identifying structural motifs governing non-HIF target engagement and expanding the VHL ligand repertoire. (2) Elucidating how non-HIF targets coordinates tissue-specific tumorigenesis in VHL-deficient versus VHL-proficient malignancies. (3) Deciphering target-bypass pathways in SMIs and the mechanisms of acquires PROTAC resistance. (4) Establishing validated predictive biomarkers—specifically prescreening for functional VHL status—to guide patient stratification. Addressing these core mechanistic and pharmacological bottlenecks will be essential to guide next-generation therapies in VHL-associated malignancies.